prednisone and HIV Coinfection studies

Prednisone: A synthetic anti-inflammatory glucocorticoid derived from CORTISONE. It is biologically inert and converted to PREDNISOLONE in the liver.
prednisone : A synthetic glucocorticoid drug that is particularly effective as an immunosuppressant, and affects virtually all of the immune system. Prednisone is a prodrug that is converted by the liver into prednisolone (a beta-hydroxy group instead of the oxo group at position 11), which is the active drug and also a steroid.

Research Excerpts

Excerpt	Relevance	Reference
" Risk factors for rash included higher pretreatment CD4 cell count, lower HIV-1 RNA level, female sex, and higher trough nevirapine concentrations."	9.10	Randomized, controlled study of the effects of a short course of prednisone on the incidence of rash associated with nevirapine in patients infected with HIV-1. ( Cahn, P; Casssetti, LI; Gigliotti, M; Hall, DB; Losso, M; McDonough, M; Montaner, JS; Robinson, PA; Wruck, J; Zala, C, 2003)
"We report a case of the successful use of corticosteroids to treat hypersensitivity caused by efavirenz in a pediatric patient."	7.72	Hypersensitivity to efavirenz treated with corticosteroids in a 6-year-old child. ( Foti, JL; Piatt, JP, 2003)
"Prednisone therapy and intravenous gamma globulin may be helpful in patients with generalized myasthenia gravis complicating HIV infection."	7.70	Seronegative myasthenia gravis and human immunodeficiency virus infection: response to intravenous gamma globulin and prednisone. ( Strong, J; Zochodne, DW, 1998)
"Prednisone improves serum creatinine and proteinuria in a substantial proportion of adults with HIV-AN."	7.69	Prednisone improves renal function and proteinuria in human immunodeficiency virus-associated nephropathy. ( Austen, JL; Carey, JT; Emancipator, SN; Gripshover, B; Herbener, T; Kalayjian, RC; Mbanefo, C; Phinney, M; Rahman, M; Salata, RA; Smith, MC; Weigel, K, 1996)
"Paradoxical tuberculosis-associated immune reconstitution inflammatory syndrome (TB-IRIS) is a frequent complication of antiretroviral therapy in resource-limited countries."	6.75	Randomized placebo-controlled trial of prednisone for paradoxical tuberculosis-associated immune reconstitution inflammatory syndrome. ( Maartens, G; Meintjes, G; Morroni, C; Oni, T; Pepper, DJ; Rangaka, MX; Rebe, K; Wilkinson, RJ, 2010)
"The appearance of rash is one of the most frequent and limiting side-effects during the first 4 weeks of treatment with nevirapine (NVP)."	6.69	Prevention of nevirapine-associated exanthema using slow dose escalation and/or corticosteroids. ( Barreiro, P; Casas, E; de Requena, DG; Estrada, V; González-Lahoz, J; Hoetelmans, R; Jimenéz-Nácher, I; Soriano, V; Téllez, MJ, 2000)
" Risk factors for rash included higher pretreatment CD4 cell count, lower HIV-1 RNA level, female sex, and higher trough nevirapine concentrations."	5.10	Randomized, controlled study of the effects of a short course of prednisone on the incidence of rash associated with nevirapine in patients infected with HIV-1. ( Cahn, P; Casssetti, LI; Gigliotti, M; Hall, DB; Losso, M; McDonough, M; Montaner, JS; Robinson, PA; Wruck, J; Zala, C, 2003)
"Prednisone therapy is highly efficacious for the treatment of idiopathic esophageal ulcer resulting in a rapid clinical response and endoscopic healing."	5.07	Comparison of two corticosteroid regimens for the treatment of HIV-associated idiopathic esophageal ulcer. ( Schwartz, DA; Wilcox, CM, 1994)
"Patients with aggressive B-cell lymphoma and MYC rearrangement at fluorescence in situ hybridization exhibit poor outcome after R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine, prednisone)."	4.12	Safety and efficacy of a dose-dense short-term therapy in patients with MYC-translocated aggressive lymphoma. ( Allione, B; Angelillo, P; Cattaneo, C; Erbella, F; Facchetti, F; Ferreri, AJM; Flospergher, E; Foppoli, M; Lleshi, A; Pagani, C; Pecciarini, L; Ponzoni, M; Re, A; Rossi, G; Sassone, M; Spina, M; Steffanoni, S; Verga, L, 2022)
" Our study aimed to investigate the prognosis and compare outcome of dose-adjusted etoposide, prednisone, vincristine, cyclophosphamide, doxorubicin, and rituximab (DA-EPOCH-R) with standard cyclophosphamide, doxorubicin, vincristine, prednisone and rituximab(R-CHOP) as front line therapy for PLHIV with diffuse large B-cell lymphoma (DLBCL) receiving modern combined antiretroviral therapy (cART)."	3.96	Clinical outcomes of people living with human immunodeficiency virus (HIV) with diffuse large B-cell lymphoma (DLBCL) in Shanghai, China. ( Chen, J; Liu, L; Qi, TK; Shen, YZ; Song, W; Sun, JJ; Tang, Y; Wang, JR; Wang, ZY; Zhang, RF, 2020)
"Use of combination antiretroviral therapy (cART) and cyclophosphamide, doxorubicin, vincristine and prednisone (CHOP) with or without rituximab for treatment of diffuse large B-cell lymphoma (DLBCL) in HIV substantially increases response rates but may also increase toxicity, possibly due to antiretroviral-antineoplastic drug interactions."	3.79	Safety and efficacy of CHOP for treatment of diffuse large B-cell lymphoma with different combination antiretroviral therapy regimens: SCULPT study. ( Kukreti, V; Laroche, M; Lemieux, B; Marcotte, S; Rouleau, D; Routy, JP; Seki, JT; Sheehan, NL; Tseng, A; Wong, AY, 2013)
"The proportion of intravenous drug abusers (IVDA) in HIV-HD (38%) is higher than in French HIV-infected population as a whole (20."	3.78	Human immunodeficiency virus associated Hodgkin's disease: report of 45 cases from the French Registry of HIV-Associated Tumors. ( Andrieu, JM; Brice, P; Colonna, P; Gastaut, JA; Lévy, R; Raphaël, M; Taillan, B; Tourani, JM, 1995)
" In this study we found that HIV-infected patients with diffuse large B-cell lymphoma treated with cyclophosphamide, hydroxydoxorubicin, vincristine and prednisone (CHOP) and HAART showed a similar response rate to chemotherapy, disease-free survival and overall survival as those of HIV-negative patients receiving CHOP."	3.73	The prognosis of HIV-infected patients with diffuse large B-cell lymphoma treated with chemotherapy and highly active antiretroviral therapy is similar to that of HIV-negative patients receiving chemotherapy. ( Feliu, E; Lloveras, N; Mate, JL; Navarro, JT; Oriol, A; Ribera, JM, 2005)
"We report a case of the successful use of corticosteroids to treat hypersensitivity caused by efavirenz in a pediatric patient."	3.72	Hypersensitivity to efavirenz treated with corticosteroids in a 6-year-old child. ( Foti, JL; Piatt, JP, 2003)
"Prednisone therapy and intravenous gamma globulin may be helpful in patients with generalized myasthenia gravis complicating HIV infection."	3.70	Seronegative myasthenia gravis and human immunodeficiency virus infection: response to intravenous gamma globulin and prednisone. ( Strong, J; Zochodne, DW, 1998)
" One patient had some improvement but was unable to tolerate the prednisone because of a severe exacerbation of anal warts."	3.69	Idiopathic colonic inflammation in AIDS: an open trial of prednisone. ( Gopal, DV; Hassaram, S; Kandel, G; Marcon, NE, 1997)
"Prednisone improves serum creatinine and proteinuria in a substantial proportion of adults with HIV-AN."	3.69	Prednisone improves renal function and proteinuria in human immunodeficiency virus-associated nephropathy. ( Austen, JL; Carey, JT; Emancipator, SN; Gripshover, B; Herbener, T; Kalayjian, RC; Mbanefo, C; Phinney, M; Rahman, M; Salata, RA; Smith, MC; Weigel, K, 1996)
"To evaluate the efficacy and safety of oral prednisone therapy for idiopathic esophageal ulcerations (IEU) associated with human immunodeficiency virus (HIV) infection."	3.68	A pilot study of oral corticosteroid therapy for idiopathic esophageal ulcerations associated with human immunodeficiency virus infection. ( Schwartz, DA; Wilcox, CM, 1992)
"Prednisone treatment during the first 4 weeks after the initiation of ART for HIV infection resulted in a lower incidence of tuberculosis-associated IRIS than placebo, without evidence of an increased risk of severe infections or cancers."	2.87	Prednisone for the Prevention of Paradoxical Tuberculosis-Associated IRIS. ( Blumenthal, L; Buyze, J; Colebunders, R; Jackson, A; Lynen, L; Maartens, G; Meintjes, G; Nair, A; Ravinetto, R; Schutz, C; Stek, C; Thienemann, F; van Loen, H; Wilkinson, RJ, 2018)
"We report a case of bacillary peliosis hepatis and secondary haemophagocytic lymphohistiocytosis due to disseminated Bartonella spp infection in a kidney-transplant recipient with well controlled HIV."	2.82	Haemophagocytic lymphohistiocytosis associated with bartonella peliosis hepatis following kidney transplantation in a patient with HIV. ( Collins, J; Doane, T; Farris, AB; Friedman-Moraco, R; Guarner, J; Marshall Lyon, G; Pouch, S; Steed, D; Woodworth, MH; Yarar, D, 2022)
"HIV-tuberculosis-associated immune reconstitution inflammatory syndrome (TB-IRIS) is an immunopathological reaction to mycobacterial antigens induced by antiretroviral therapy."	2.77	Corticosteroid-modulated immune activation in the tuberculosis immune reconstitution inflammatory syndrome. ( Colebunders, R; Conesa-Botella, A; Maartens, G; Matthews, K; Meintjes, G; Morroni, C; Pepper, DJ; Rangaka, MX; Rebe, K; Seldon, R; Skolimowska, KH; Tadokera, R; Wilkinson, KA; Wilkinson, RJ, 2012)
" The pharmacokinetic comparability of Prolastin-C to Prolastin was assessed in subjects with AAT deficiency."	2.75	Pharmacokinetic comparability of Prolastin®-C to Prolastin® in alpha₁-antitrypsin deficiency: a randomized study. ( Brantly, ML; Campos, MA; Chapman, KR; Kueppers, F; Sandhaus, RA; Stocks, JM; Strange, C; Turino, G; Wang-Smith, L, 2010)
"Paradoxical tuberculosis-associated immune reconstitution inflammatory syndrome (TB-IRIS) is a frequent complication of antiretroviral therapy in resource-limited countries."	2.75	Randomized placebo-controlled trial of prednisone for paradoxical tuberculosis-associated immune reconstitution inflammatory syndrome. ( Maartens, G; Meintjes, G; Morroni, C; Oni, T; Pepper, DJ; Rangaka, MX; Rebe, K; Wilkinson, RJ, 2010)
"Complete pharmacokinetics and pharmacodynamic analysis was determined in 19 patients during 38 cycles of chemotherapy: 19 cycles with CHOP and 19 CHOP + HAART in a crossover-designed study."	2.71	Effect of highly active antiretroviral therapy (HAART) on pharmacokinetics and pharmacodynamics of doxorubicin in patients with HIV-associated non-Hodgkin's lymphoma. ( Boiocchi, M; Cattarossi, G; Corona, G; Di Gennaro, G; Tirelli, U; Toffoli, G; Vaccher, E, 2004)
" In addition, the effects on viral load, CD4 counts, and opportunistic infections were examined with the use of combination chemotherapy combined with HAART."	2.70	Chemotherapy for human immunodeficiency virus-associated non-Hodgkin's lymphoma in combination with highly active antiretroviral therapy. ( Ambinder, R; Flexner, C; Grochow, L; Hamzeh, F; Harrington, W; Herndier, B; Kaplan, L; Lee, J; Levine, A; Ratner, L; Redden, D; Scadden, D; Straus, D; Tan, B; Tang, S, 2001)
"The appearance of rash is one of the most frequent and limiting side-effects during the first 4 weeks of treatment with nevirapine (NVP)."	2.69	Prevention of nevirapine-associated exanthema using slow dose escalation and/or corticosteroids. ( Barreiro, P; Casas, E; de Requena, DG; Estrada, V; González-Lahoz, J; Hoetelmans, R; Jimenéz-Nácher, I; Soriano, V; Téllez, MJ, 2000)
"58% of the non-Hodgkin's lymphomas occurred in patients with marked immunodeficiency, 85% were high grade malignancies and 47% had primary extranodal disease."	2.67	[Malignant lymphoma associated with HIV infection]. ( Becker, K; Clemens, MR; Fischer, T; Helm, EB; Knauf, W; Mitrou, PS; Pohl, C; Schrappe-Bächer, M; Serke, M; Westerhausen, M, 1991)
"Limited comparative data exist for the treatment of HIV-associated non-Hodgkin lymphoma."	2.49	Treatment factors affecting outcomes in HIV-associated non-Hodgkin lymphomas: a pooled analysis of 1546 patients. ( Barta, SK; Boue, F; Dunleavy, K; Galicier, L; Garcia, O; Kaplan, LD; Lee, JY; Little, RF; Morgades, M; Mounier, N; Navarro, JT; Noy, A; Oriol, A; Ratner, L; Remick, SC; Ribera, JM; Sparano, JA; Spina, M; Tamari, R; Tirelli, U; Wang, D; Weiss, R; Wilson, WH; Wyen, C; Xue, X, 2013)
"Dermatomyositis is a rheumatologic illness that very infrequently occurs and during our review of literature only three other cases were reported."	2.47	Dermatomyositis and HIV infection: case report and review of the literature. ( Carroll, MB; Holmes, R, 2011)
"Past medical conditions included type 2 diabetes."	1.91	Primary esophageal diffuse large B-cell lymphoma. ( Álvarez Martínez, P; Del Caño Cerdán, C; García González, P; García Riesco, E; Nieto-Jara, A; Ramos Martínez, PJ, 2023)
"The risk of malignant lymphomas is markedly increased in HIV-infected persons even in the era of effective combination antiretroviral therapy."	1.62	[Diagnosis and treatment of HIV-associated lymphoma: Update 202]. ( Hentrich, M, 2021)
"Grade 3/4 neutropenia was observed in 26% of cycles and in 65% of patients."	1.56	Modified EPOCH for high-risk non-Hodgkin lymphoma in sub-Saharan Africa. ( Chikasema, M; Chimzimu, F; Chiyoyola, S; Ellis, GK; Fedoriw, G; Gopal, S; Kaimila, B; Kampani, C; Kasonkanji, E; Mhango, W; Montgomery, ND; Mtangwanika, A; Mulenga, M; Nicholas, S; Nyasosela, R; Nyirenda, R; Painschab, MS; Randall, C; Tewete, B; Tomoka, T; Westmoreland, KD; Zuze, T, 2020)
"He had multiple prior episodes of cryptococcal meningitis with complications necessitating ventriculoperitoneal shunt placement and was on suppressive fluconazole when he developed worsening brain manifestations."	1.56	Case Report: A Case of Severe Cryptococcal Immune Reconstitution Inflammatory Syndrome Presenting with Brain and Intradural Abscesses in an HIV Patient. ( Jeng, A; Kalinoski, T; Malenfant, J; Yim, C, 2020)
"Epidermolysis bullosa acquisita is a chronic subepidermal blistering disease associated with autoimmunity to type-VII collagen within anchoring fibrils located at the dermo-epidermal junction."	1.46	A rare occurrence of epidermolysis bullosa acquisita in a patient with retroviral disease. ( Aditi, C; Chitra, N; Swagata, T; Uddhao, Z, 2017)
"However, autoimmune hepatitis (AIH) in patients with HIV has rarely been reported."	1.46	Autoimmune hepatitis in patients with human immunodeficiency virus (HIV): Case reports of a rare, but important diagnosis with therapeutic implications. ( Beattie, A; Green, RM; Kia, L, 2017)
"The diagnosis of stage IV Burkitt lymphoma with predominant extranodal cardiac involvement was withheld wherefore promptly aggressive therapy was started according to the GMALL B-NHL86 protocol."	1.46	Aggressive extensive cardiac mass in an HIV-1-infected patient: should we go for comfort therapy? ( De Pauw, M; Demulier, L; Steel, E; Terryn, W; Vandekerckhove, L; Vercammen, J; Vervloet, DM, 2017)
"Here we present a case of plasmablastic lymphoma with primary site being maxillary sinus, a rare location."	1.43	Primary Maxillary Sinus Plasmablastic Lymphoma in HIV/AIDS. ( Basavaraj, A; Kadam, DB; Kadam, M, 2016)
"Clinically, primary cutaneous plasmablastic lymphoma presents as non-specific cutaneous lesions (purple nodules, erythematous infiltrated plaques)."	1.43	Plasmablastic lymphoma: an atypical cutaneous presentation of a rare entity. ( Carvalho, S; Coelho, A; Lima, M; Mesquita, B; Mota, F; Selores, M; Velho, G, 2016)
"Bilateral lower motor neuron type facial palsy is an unusual neurological disorder."	1.42	Isolated and bilateral simultaneous facial palsy disclosing early human immunodeficiency virus infection. ( Sathirapanya, P, 2015)
" Prospective pharmacokinetic studies to devise a rational dosing strategy for vinblastine in patients receiving ritonavir/lopinavir are warranted."	1.38	Incidence, predictors and significance of severe toxicity in patients with human immunodeficiency virus-associated Hodgkin lymphoma. ( Boro, J; Cheung, MC; Ezzat, HM; Harris, M; Hicks, LK; Leitch, HA; Lima, VD; Montaner, JS, 2012)
"We report a case of immune reconstitution inflammatory syndrome (IRIS) in a 32-year-old man infected with human immunodeficiency virus and Leishmania guyanensis."	1.35	Tegumentary leishmaniasis as the cause of immune reconstitution inflammatory syndrome in a patient co-infected with human immunodeficiency virus and Leishmania guyanensis. ( Botileiro, SF; Chrusciak-Talhari, A; Dietze, R; Ferreira, LC; Ribeiro-Rodrigues, R; Santos, LO; Silva, RM; Talhari, C; Talhari, S, 2009)
"Multicentric Castleman's disease (MCD) in human immunodeficiency virus (HIV)-infected patients is an aggressive form of lymphoproliferative disorder that usually has a rapidly fatal outcome."	1.35	Successful treatment of aggressive HIV-associated multicentric Castleman's disease: a case report. ( Ahmed, MS; Cheng, YC; Flejsierowicz, M; Kotov, P, 2008)
"Hodgkin lymphoma is considered a common type of non-AIDS defining tumor among patients infected with HIV, commonly presenting as a widespread disease and with different pathologic features compared with Hodgkin lymphoma in the general population."	1.34	Hodgkin lymphoma among patients infected with HIV in post-HAART era. ( Buccheri, V; Calore, EE; Chamone, DA; Pessoa, VP; Pracchia, LF; Tanaka, PY, 2007)
" Seven patients received indinavir at a dosage of 800 mg three times daily and three patients received nelfinavir at a dosage of 750 mg three times daily."	1.33	Pharmacokinetic interaction between chemotherapy for non-Hodgkin's lymphoma and protease inhibitors in HIV-1-infected patients. ( Bassetti, D; Bassetti, M; Cinelli, R; Cruciani, M; Di Gennaro, G; Gatti, G; Tirelli, U; Vaccher, E, 2005)
"Although infrequent, metastatic Crohn's disease should be suspected in cases of recalcitrant ulcerative conditions, even in the absence of intestinal disease."	1.33	Metastatic Crohn's disease mimicking genital pyoderma gangrenosum in an HIV patient. ( Avilés-Izquierdo, JA; Lázaro-Ochaita, P; Longo-Imedio, I; Suárez-Fernández, R, 2005)
"Multiple myeloma was diagnosed at an advanced stage in the three cases."	1.32	[Multiple myeloma and HIV infection: report of 3 cases]. ( Elira Dokekias, A; Malanda, F; Moutschen, M; Moyikoua, A; Purhuence, MF, 2004)
"Progressive multifocal leukoencephalopathy was diagnosed by cerebrospinal fluid polymerase chain reaction for JC virus and magnetic resonance imaging of the brain."	1.32	Progressive multifocal leukoencephalopathy after initiation of highly active antiretroviral therapy in a child with advanced human immunodeficiency virus infection: a case of immune reconstitution inflammatory syndrome. ( Corcoran, C; Eley, BS; Hussey, GD; Ndondo, AP; Nuttall, JJ; Wilmshurst, JM; Yeats, J, 2004)
"Relapsing polychondritis is a rare autoimmune disease characterized by inflammation and degeneration of cartilaginous tissue."	1.32	Relapsing polychondritis in HIV-infected patients: a report of two cases. ( Berger, T; Dolev, JC; Maurer, TA; Ramirez, LE; Reddy, SG, 2004)
"Prednisone is commonly used to treat rash, a potentially harmful side effect of nevirapine."	1.31	Nevirapine, prednisone and rash. ( , 2000)
"Peripheral facial palsy has been considered as a possible neurological complication of the early stage of HIV infection but the number of reported cases in the literature is limited."	1.31	Bilateral peripheral facial palsy secondary to lymphoma in a patient with HIV/AIDS: a case report and literature review. ( de Almeida, SM; Leite, AG; Leite, PG; Sasaki, Md, 2002)
"Parotid cysts are an unrecognized sign of early HIV infection."	1.30	Response of lymphoepithelial parotid cysts to antiretroviral treatment in HIV-infected adults. ( Craven, DE; Duncan, RA; Hirschhorn, LR; Jhamb, K; O'Hara, CJ; Steger, KA; Stram, JR, 1998)
"Two had cutaneous non-Hodgkin's lymphoma while one had Hodgkin's lymphoma."	1.30	HIV-associated lymphoma: report of three cases. ( Mwangi, JW, 1999)
"The occurrence of HIV associated non-Hodgkin's lymphoma (NHL) is a well recognized event."	1.29	Hodgkin's disease and non-Hodgkin's lymphoma in an HIV positive patient. ( Brody, J; Goh, JC; Kaplan, MH; Koduru, P; Lichtman, SM; Susin, M, 1993)
"Multiple ulcers were identified in 57% of endoscopies."	1.29	Endoscopic characterization of idiopathic esophageal ulceration associated with human immunodeficiency virus infection. ( Schwartz, DA; Wilcox, CM, 1993)
"Three patients with Hodgkin's disease, mixed cellularity subtype, plus infection by human immunodeficiency virus are presented."	1.28	[Hodgkin's disease and infection with human immunodeficiency virus]. ( Auguet Quintillá, T; Gallén Castillo, M; Pedro-Botet Montoya, J; Planas Domingo, J, 1992)

Research

Studies (188)

Authors

Clinical Trials (10)

Trial Overview

Trial Outcomes

Complete Response Proportion as Measured by Tumor Response After Completion of Study Treatment

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	44 (23.40)	18.2507
2000's	57 (30.32)	29.6817
2010's	61 (32.45)	24.3611
2020's	26 (13.83)	2.80

Authors	Studies
Kaviani, A	1
Khansari Nejad, N	1
Akour, A	1
AlMuhaissen, SA	1
Nusair, MB	1
Al-Tammemi, AB	1
Mahmoud, NN	1
Jalouqa, S	1
Alrawashdeh, MN	1
Shanahan, JP	1
Moore, CM	1
Kampf, JW	1
Szymczak, NK	1
Guo, J	1
Wang, H	1
Luo, Y	1
An, H	1
Zhang, Z	2
Liu, G	1
Li, J	1
Metcalfe, GD	1
Smith, TW	1
Hippler, M	1
Ayala Izurieta, JE	1
Márquez, CO	1
García, VJ	1
Jara Santillán, CA	1
Sisti, JM	1
Pasqualotto, N	1
Van Wittenberghe, S	1
Delegido, J	1
Kubo, Y	1
Kitagawa, Y	1
Miyazaki, T	1
Sohda, M	1
Yamaji, T	1
Sakai, M	1
Saeki, H	1
Nemoto, K	1
Oyama, T	2
Muto, M	1
Takeuchi, H	1
Toh, Y	1
Matsubara, H	1
Mano, M	1
Kono, K	1
Kato, K	1
Yoshida, M	1
Kawakubo, H	1
Booka, E	1
Yamatsuji, T	1
Kato, H	1
Ito, Y	1
Ishikawa, H	1
Ishihara, R	1
Tsushima, T	1
Kawachi, H	1
Kojima, T	1
Kuribayashi, S	1
Makino, T	1
Matsuda, S	1
Doki, Y	1
Ma, P	1
Tang, X	1
Zhang, L	2
Wang, X	1
Wang, W	1
Zhang, X	1
Wang, S	2
Zhou, N	1
Dodd, J	1
Jordan, R	1
Makhlina, M	1
Pesco Koplowitz, L	1
Koplowitz, B	1
Barnett, K	1
Yang, WH	1
Spana, C	1
Buchanan, SW	1
Mafa-Attoye, T	1
Dunfield, K	1
Thevathasan, NV	1
Isaac, ME	1
Wu, X	2
Huang, JW	1
Su, BK	1
Yuan, L	1
Zheng, WQ	1
Zhang, H	2
Zheng, YX	1
Zhu, W	1
Chou, PT	1
Manso, AP	1
De Morais, DC	1
Yamamoto, K	1
Owen, G	1
de Carvalho, RM	1
Palma-Dibb, RG	1
Brown, JC	1
Yang, S	2
Mire, EF	1
Miele, L	1
Ochoa, A	1
Zabaleta, J	1
Katzmarzyk, PT	1
Moi, CT	1
Bhowmick, S	1
Qureshi, M	1
Wang, K	1
Feng, B	1
Yang, Y	1
Chen, Y	1
Wang, Y	2
Yang, L	2
Jiang, K	1
James, TD	1
Chaturvedi, V	1
Postiglione, WM	1
Chakraborty, RD	1
Yu, B	1
Tabiś, W	1
Hameed, S	1
Biniskos, N	1
Jacobson, A	1
Zhou, H	1
Greven, M	1
Ferry, VE	1
Leighton, C	1
Wu, F	1
Lei, H	1
Chen, G	1
Chen, C	1
Song, Y	1
Cao, Z	1
Zhang, C	2
Zhou, J	1
Lu, Y	1
Pappone, C	1
Santinelli, V	1
Mecarocci, V	1
Tondi, L	1
Ciconte, G	1
Manguso, F	1
Sturla, F	1
Vicedomini, G	1
Micaglio, E	1
Anastasia, L	1
Pica, S	1
Camporeale, A	1
Lombardi, M	1
Shieh, PB	1
Elfring, G	1
Trifillis, P	1
Santos, C	1
Peltz, SW	1
Parsons, JA	1
Apkon, S	1
Darras, BT	1
Campbell, C	1
McDonald, CM	1
Galaviz, KI	1
Shah, NS	1
Gutierrez, M	2
Collins, LF	1
Lahiri, CD	1
Moran, CA	1
Szabo, B	1
Sumitani, J	1
Rhodes, J	1
Marconi, VC	1
Nguyen, ML	1
Cantos, VD	1
Armstrong, WS	1
Colasanti, JA	1
Jain, A	1
Arun, VA	1
Bal, A	1
Malhotra, P	1
Rapiti, N	2
Peer, N	1
Abdelatif, N	2
Rapiti, P	1
Moosa, Y	1
Steed, D	1
Collins, J	1
Farris, AB	1
Guarner, J	1
Yarar, D	1
Friedman-Moraco, R	1
Doane, T	1
Pouch, S	1
Marshall Lyon, G	1
Woodworth, MH	1
Ferreri, AJM	1
Angelillo, P	1
Erbella, F	1
Cattaneo, C	1
Verga, L	1
Lleshi, A	1
Allione, B	1
Ponzoni, M	1
Facchetti, F	1
Pagani, C	1
Foppoli, M	1
Pecciarini, L	1
Sassone, M	1
Steffanoni, S	1
Flospergher, E	1
Rossi, G	2
Spina, M	7
Re, A	1
Rapiti, A	1
Moosa, MY	1
Cabrera, ME	1
Peña, C	1
Leon, P	1
Lois, V	1
Rojas, H	1
Vega, V	1
Pizarro, A	1
Calderon, S	1
Rojas, C	1
Aspillaga, A	1
Gonzalez, ML	1
Intriago, M	1
Rojas, B	1
Hales, C	1
Oliva, J	1
Romero, M	1
Capurro, M	1
Castillo, JJ	4
Álvarez Martínez, P	1
Ramos Martínez, PJ	1
García González, P	1
Nieto-Jara, A	1
Del Caño Cerdán, C	1
García Riesco, E	1
Vaughan, J	1
Wiggill, T	1
Lawrie, D	1
Machaba, M	1
Patel, M	1
Musimar, Z	1
Mpetani, M	1
Abramson, JS	2
Chabner, BA	2
Mohamed, Z	1
Ssemmanda, S	1
Musubire, AK	1
Geel, J	1
van Zyl, A	1
Plessis, JD	1
Hendricks, M	1
Goga, Y	1
Carr, A	1
Neethling, B	1
Hramyka, A	1
Omar, F	1
Mathew, R	1
Louw, L	1
Naidoo, T	1
Ngcana, T	1
Schickerling, T	1
Netshituni, V	1
Madzhia, E	1
du Plessis, L	1
Kelsey, T	1
Ballot, DE	1
Metzger, ML	1
Philippe, L	1
Lancar, R	1
Laurent, C	1
Algarte-Genin, M	1
Chassagne-Clément, C	1
Fabiani, B	1
Pierre Chenard, M	1
Lazure, T	1
Parrens, M	1
Charlotte, F	1
Delattre, C	1
Gibault, L	1
Capron, F	1
Goubin-Versini, I	1
Petitjean, B	1
Boué, F	2
Mounier, N	2
Costello, R	1
Costagliola, D	1
Prevot, S	1
Besson, C	1
Zuze, T	2
Ellis, GK	1
Kasonkanji, E	3
Kaimila, B	3
Nyasosela, R	2
Nyirenda, R	1
Tomoka, T	3
Mulenga, M	2
Chikasema, M	2
Tewete, B	1
Mtangwanika, A	1
Chiyoyola, S	1
Chimzimu, F	2
Kampani, C	2
Mhango, W	1
Nicholas, S	1
Randall, C	1
Montgomery, ND	3
Fedoriw, G	1
Westmoreland, KD	2
Painschab, MS	2
Gopal, S	3
Yousif, P	1
Kotecha, A	1
Thakur, A	1
Ismail, HM	1
Stek, C	3
Allwood, B	1
Du Bruyn, E	1
Buyze, J	2
Schutz, C	2
Thienemann, F	2
Lombard, A	1
Wilkinson, RJ	6
Meintjes, G	7
Lynen, L	2
Sparano, JA	3
Lee, JY	4
Kaplan, LD	5
Ramos, JC	3
Ambinder, RF	2
Wachsman, W	1
Aboulafia, D	2
Noy, A	4
Henry, DH	2
Ratner, L	5
Cesarman, E	3
Chadburn, A	2
Mitsuyasu, R	3
Kalinoski, T	1
Malenfant, J	1
Yim, C	1
Jeng, A	1
Sun, S	1
Xu, B	1
Zhang, Q	1
Zhao, CS	1
Ma, R	1
He, J	1
Zhang, Y	1
Reid, EG	2
Siegel, ER	1
Moore, PC	1
Rubinstein, PG	1
Durand, CM	1
Baiocchi, R	1
Kaplan, L	2
Capoferri, AA	1
Modi, AR	1
Koval, CE	1
Taege, AJ	1
Modaresi Esfeh, J	1
Eghtesad, B	1
Narayanan Menon, KV	1
Quintini, C	1
Miller, C	1
Habbous, S	1
Guo, H	1
Beca, J	1
Dai, WF	1
Isaranuwatchai, W	1
Cheung, M	1
Chan, KKW	1
Okello, CD	1
Omoding, A	1
Ddungu, H	1
Mulumba, Y	1
Orem, J	1
Sun, JJ	1
Liu, L	1
Wang, JR	1
Shen, YZ	1
Qi, TK	1
Wang, ZY	1
Tang, Y	1
Song, W	1
Chen, J	1
Zhang, RF	1
Ke, YL	1
Hsiao, HH	1
Cho, SF	1
Wu, CC	1
Hentrich, M	3
Harrison, MJ	1
Brice, N	1
Scott, C	1
Kobayashi, H	1
Miyagi, N	1
Uddhao, Z	1
Aditi, C	1
Chitra, N	1
Swagata, T	1
Conconi, A	1
Zucca, E	1
Margiotta-Casaluci, G	1
Darling, K	1
Hasse, B	1
Battegay, M	2
Staehelin, C	1
Novak, U	1
Schmid, P	1
Scherrer, A	1
Dirnhofer, S	1
Kwee, I	1
Nassi, L	1
Cavalli, F	1
Gaidano, G	1
Bertoni, F	1
Bernasconi, E	1
Taeb, AM	1
Sill, JM	1
Derber, CJ	1
Hooper, MH	1
Walker, NF	1
Wasserman, S	1
Milligan, MG	1
Bigger, E	1
Sohani, AR	1
Zola, M	1
Kayembe, MKA	1
Medhin, H	1
Suneja, G	1
Lockman, S	1
Dryden-Peterson, SL	1
Feng, J	1
Xu, L	1
Dong, HJ	1
Zhang, N	1
Bai, QX	1
Liang, R	1
Shu, MM	1
Chen, XQ	1
Gu, HT	1
Gao, GX	1
Coomes, EA	1
Heendeniya, A	1
Bunce, PE	1
Blumenthal, L	1
Ravinetto, R	1
van Loen, H	1
Nair, A	1
Jackson, A	1
Colebunders, R	3
Maartens, G	4
Cattaneo, D	1
Cheli, S	1
Fusi, M	1
Clementi, E	1
Gervasoni, C	1
Waswa, P	1
El-Mallawany, NK	1
Fedoriw, Y	2
Ron, R	1
Ruz-Caracuel, I	1
García, E	1
Montes-Ramírez, ML	1
Lin, AY	1
Chun, V	1
Dhamija, A	1
Bordin-Wosk, T	1
Kadakia, A	1
Wong, AY	1
Marcotte, S	1
Laroche, M	1
Sheehan, NL	1
Kukreti, V	1
Routy, JP	1
Lemieux, B	1
Seki, JT	1
Rouleau, D	1
Tseng, A	1
Barta, SK	1
Xue, X	1
Wang, D	1
Tamari, R	1
Ribera, JM	5
Tirelli, U	9
Weiss, R	1
Galicier, L	1
Wilson, WH	1
Wyen, C	3
Oriol, A	2
Navarro, JT	5
Dunleavy, K	1
Little, RF	2
Garcia, O	2
Morgades, M	3
Remick, SC	1
Levine, AM	2
Narita, K	1

Trial	Phase	Enrollment	Study Type	Start Date	Status
A Randomized Phase II Trial of EPOCH Given Either Concurrently or Sequentially With Rituximab in Patients With Intermediate- or High-Grade HIV-Associated B-cell Non-Hodgkin's Lymphoma[NCT00049036]	Phase 2	106 participants (Actual)	Interventional	2003-03-31	Completed
A Sequential Phase I/Randomized Phase II Trial of Vorinostat and Risk-Adapted Chemotherapy With Rituximab in HIV-Related B-Cell Non-Hodgkin's Lymphoma[NCT01193842]	Phase 1/Phase 2	107 participants (Actual)	Interventional	2010-10-06	Completed
Preventing Tuberculosis-associated Immune Reconstitution Inflammatory Syndrome in High-risk Patients: a Randomized Placebo-controlled Trial of Prednisone[NCT01924286]	Phase 3	240 participants (Actual)	Interventional	2013-08-30	Completed
A Multicentre, Randomized Phase III Study of Thalidomide Maintenance Treatment in Patients With Diffuse Large B-cell Lymphoma[NCT03016000]	Phase 3	226 participants (Anticipated)	Interventional	2017-07-26	Recruiting
A Randomized Double Blind Placebo Controlled Trial of Adjunctive Dexamethasone for the Treatment of HIV-infected Adults With Tuberculous Meningitis[NCT03092817]	Phase 3	520 participants (Actual)	Interventional	2017-05-25	Active, not recruiting
A Double-Blind Randomized Placebo Controlled Trial for Prevention of Tuberculosis-Immune Reconstitution Inflammatory Syndrome With Non-Steroid Anti-Inflammatory Drugs (NSAIDs) in HIV-Infected Adults[NCT02060006]	Phase 3	200 participants (Anticipated)	Interventional	2014-04-30	Recruiting
Multi-center, Randomized, Double-blind, Crossover Trial to Evaluate the Pharmacokinetic Comparability of Alpha-1 MP to Prolastin in Subjects With Alpha1-antitrypsin Deficiency.[NCT00295061]	Phase 3	24 participants (Actual)	Interventional	2006-05-31	Completed
A Phase II Trial of Doxil, Rituximab, Cyclophosphamide, Vincristine, and Prednisone (DR-COP) in Patients With Newly Diagnosed AIDS-Associated B-Cell Non-Hodgkin's Lymphoma[NCT00389818]	Phase 2	43 participants (Actual)	Interventional	2007-01-31	Completed
"Prospective Non Randomized Study With Chemotherapy in Patients With Hodgkin's Disease and HIV Infection: Stanford V Regimen For Low Risk Patients, EBVP Regimen For High Risk Patients"[NCT00003262]	Phase 2	30 participants (Anticipated)	Interventional	1997-05-31	Active, not recruiting
LINFOTARGAM: First-line Treatment With Dose-dense Chemotherapy Plus Rituximab (R-CHOP/14) and Highly Active Antiretroviral Therapy (HAART) in Patients With Diffuse Large B Cell Lymphoma (DLBCL) and Infection With the Human Immunodeficiency Virus (HIV)[NCT00466258]	Phase 4	50 participants (Anticipated)	Interventional	2006-10-31	Completed
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Complete response defined by the International Response Criteria for Non-Hodgkin's Lymphoma (NCT00049036)
Timeframe: 60 days

Event-free Survival (EFS) (Phase II)

Intervention	proportion (Number)
EPOCH + Concurrent Rituximab	0.69
EPOCH Followed by Rituximab	0.53

The percentage of participants surviving without events (relapse or death) one year after starting treatment. (NCT01193842)
Timeframe: 1 year

Overall Survival (OS) (Phase II)

Intervention	percentage of participants (Number)
Phase II: VR-DA-EPOCH	75.6
Phase II: DA-R-EPOCH	82.2

The percentage of participants surviving one year after starting treatment. (NCT01193842)
Timeframe: 1 year

Percentage of Participants With Complete Response (CR) as Assessed by Response Evaluation Criteria in Solid Tumors (Phase II)

Intervention	percentage of participants (Number)
Phase II: VR-DA-EPOCH	77.6
Phase II: DA-R-EPOCH	86.7

"Percentage of participants with complete response as assessed by Response Evaluation Criteria in Solid Tumors (Phase II) according to treatment arm. Participants are planned to be treated for a total of 6 cycles (21 day cycle length). Participants with CR after Cycle 4 will receive two additional cycles of chemotherapy and complete 6 cycles of chemotherapy. Participants who achieve a partial response (PR) only after Cycle 4 may continue on protocol therapy or they may be removed from the study at the AMC discretion of the physician (local Principal Investigator). Participants with stable disease after 4 cycles (i.e., who did not achieve at least a PR) or progressive disease at any time will be removed from study.~In phase II, there are two arms: Vorinostat RPTD+rituximab-DA-EPOCH arm (VR-DA-EPOCH) and Rituximab-DA-EPOCH arm (DA-R-EPOCH)." (NCT01193842)
Timeframe: Up to 6 months

Recommended Phase II Dose of Vorinostat Determined According to Dose-limiting Toxicities Graded Using Common Terminology Criteria for Adverse Events Version 4.0 (CTCAE v4.0) (Phase I)

Intervention	percentage of participants (Number)
Phase II: VR-DA-EPOCH	67.5
Phase II: DA-R-EPOCH	76.2

Recommended phase II dose of vorinostat is defined as the dose level at which 0/6 or 1/6 subjects experience dose limiting toxicity (DLT) with the next higher dose having at least 2/3 or 2/6 subjects encountering DLT (Phase I). Toxicities will be graded according to the National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) Version 4.0. Using a 3+3 design, the recommended phase II dose is defined as the level at which 0/6 or 1/6 patients experiences at dose-limiting toxicity in the first cycle. (NCT01193842)
Timeframe: 21 days

Change in CD8 Cell Counts (Phase I)

Intervention	Mg per day of Vorinostat (Number)
Phase I: VR-DA-EPOCH	300

Differences from baseline (specified follow-up assessment minus baseline) in absolute CD8 counts. (NCT01193842)
Timeframe: Baseline up to 12 months

Change in Plasma Associated Human Immunodeficiency Virus (HIV)-1 Ribonucleic Acid (RNA) (Phase I)

Intervention	cells/mm^3 (Median)
	End of cycle 2	Treatment discontinuation	6-month follow-up	12-month follow-up
Phase I: VR-CHOP, Dose Level 1	-172	-81	-16	128
Phase I: VR-DA-EPOCH, Dose Level 1	35.5	-164.5	-56	604
Phase I: VR-DA-EPOCH, Dose Level 2	-115	211	275	154

Differences from baseline (specified follow-up assessment minus baseline) in HIV viral load. Undetectable viral load results were treated as 0 values. (NCT01193842)
Timeframe: Baseline up to 12 months

Changes in Absolute CD4 Cell Counts (Phase I)

Intervention	copies per milliliter (Median)
	End of cycle 2	Treatment discontinuation	6-month follow-up	12-month follow-up
Phase I: VR-CHOP, Dose Level 1	28	0	0	0
Phase I: VR-DA-EPOCH, Dose Level 1	-14518	-4517	-55116	0
Phase I: VR-DA-EPOCH, Dose Level 2	-12.5	0	0	0

Differences from baseline (specified follow-up assessment minus baseline) in absolute CD4 counts. (NCT01193842)
Timeframe: Baseline up to 12 months

Changes in Epstein-Barr Virus (EBV) Viral Load

Intervention	cell/mm^3 (Median)
	End of cycle 2	Treatment discontinuation	6-month follow-up	12-month follow-up
Phase I: VR-CHOP, Dose Level 1	-218	-190	-175	-84
Phase I: VR-DA-EPOCH, Dose Level 1	92	-39	76	169
Phase I: VR-DA-EPOCH, Dose Level 2	-9	-29	31	31

Differences from baseline (specified follow-up assessment minus baseline) in EBV viral load. (NCT01193842)
Timeframe: Baseline up to 12 months

Changes in Human Herpes Virus (HHV)-8 Viral Load

Intervention	IU/mL (Median)
	End of Cycle 2	At treatment discontinuation	6-month follow-up	12-month follow-up
Phase I: VR-DA-EPOCH, Dose Level 1	0	0	0	0
Phase I: VR-DA-EPOCH, Dose Level 2	-2436.1	-1.92	-1.92	-1.15
Phase II, DA-R-EPOCH	0	-0.28	0	-2.7
Phase II, VR-DA-EPOCH	-0.61	-2.9	-1.55	-0.56

Differences from baseline (specified follow-up assessment minus baseline) in (HHV)-8 viral load. (NCT01193842)
Timeframe: Baseline up to 12 months

Changes in Human Herpes Virus (HHV)-8 Viral Load

Intervention	copies per 100uL (Median)
	12-month follow-up
Phase II: VR-DA-EPOCH	0

Differences from baseline (specified follow-up assessment minus baseline) in (HHV)-8 viral load. (NCT01193842)
Timeframe: Baseline up to 12 months

Changes in Human Immunodeficiency Virus (HIV) Viral Load

Intervention	copies per 100uL (Median)
	At treatment discontinuation	6-month follow-up	12-month follow-up
Phase II: DA-R-EPOCH	0	0	0

Percentage of Participant Experiencing Adverse Events (AEs) for Each Treatment Arm as Assessed by Common Terminology Criteria for Adverse Events Version 4.0 (CTCAE v4.0) (Phase II)

Intervention	median change in copies per mL (Median)
	End of Cycle 2	At treatment discontinuation	6-month follow-up	12-month follow-up
Phase II: DA-R-EPOCH	-25	-22.5	-18	-20
Phase II: VR-DA-EPOCH	-20	-87	-20	0

The percentage of participants with AEs and their worst severity will be tabulated for each treatment arm. If a participant has more than one AE, the most severe AE is analyzed. All adverse events will be assessed by the investigator from the first dose of protocol therapy through the post-treatment discontinuation visit. Participants are planned to be treated for a total of 6 cycles (21 day cycle length), or roughly 4 months. After this evaluation, assessment and reporting of AEs will only be required for all grade 5 AEs and any serious AE (SAE) that the investigator considers related to protocol therapy. (NCT01193842)
Timeframe: Up to 5 years

Pharmacokinetic Clearance (Phase I)

Intervention	percentage of participants (Number)
	Death	Life-threatening	Severe	Moderate	Mild
Phase II: DA-R-EPOCH	20.0	28.9	31.1	17.8	0
Phase II: VR-DA-EPOCH	28.9	37.8	20.0	8.9	2.2

Serial plasma samples for pharmacokinetic analysis were collected at 24-48, 48-72, and 72-96 hours after the start of the first chemotherapy infusion. Doxorubicin, etoposide, and vincristine concentrations were determined using a validated liquid chromatography-tandem mass spectrometry method. The clearance was determined by dividing the drug-infusion rate by the steady-state concentrations, which was the average of the three time points. (NCT01193842)
Timeframe: 24-48, 48-72, and 72-96 hours after the start of the first chemotherapy infusion

Tumor Response (Phase I)

Intervention	Liter/hour (Mean)
	Doxorubicin	Etoposide	Vincristine
Phase I: VR-DA-EPOCH, Dose Level 1	78.6	3.0	22.4
Phase I: VR-DA-EPOCH, Dose Level 2	76.0	2.4	16.8

The percentage of participants whose best tumor response is complete response (CR) or partial response (PR). Based on clinical, radiologic (CT), and pathologic criteria, CR requires 1) complete disappearance of all detectable disease and disease-related symptoms if present before therapy, 2) bone marrow aspirate and biopsy to confirm a CR if initially positive or if clinically indicated by new abnormalities in the peripheral blood counts or blood smear, 3) negative PET results, depending on typically, variably, or unknown pre-treatment FDG status, and 4) spleen and/or liver, if considered to be enlarged before therapy on physical examination or CT scan, not being palpable on physical examination and considered normal size by imaging studies, and nodules related to lymphoma disappeared. PR includes 1) ≥50% decrease in sum of product of diameters (SPD), 2) no increase in size of nodes, liver, or spleen, 3) splenic/hepatic nodules regressed by ≥ 50% SPD, 4) no new sites of disease (NCT01193842)
Timeframe: Up to 2 years post treatment

Alpha-1 MP vs. Prolastin® of Area Under the Curve (AUC) From Day 0 to Day 7

Intervention	percentage of participants (Number)
	Complete response	Partial Response
Phase I: Arm C (VR-CHOP) Dose Level 1	100	0
Phase I: VR-DA-EPOCH, Dose Level 1	83.3	16.7
Phase I: VR-DA-EPOCH, Dose Level 2	83.3	16.7

"The primary objective of this study was to demonstrate the pharmacokinetic comparability (geometric least square mean ratio of AUC between the Alpha-1 MP vs. Prolastin®, 90% confidence interval falls within 0.80-1.25, FDA Guidance as being bioequivalent between two treatments) of Alpha-1 MP to Prolastin® in subjects with alpha-1-anti-trypsin (AAT) deficiency by comparing AUC from Day 0 to Day 7 of plasma Alpha1-PI measured by the functional activity (potency) assay. AUC from Day 0 to Day 7 was calculated at steady state at the end of the first and second 8-week treatment periods during the 16-week double-blind, crossover phase." (NCT00295061)
Timeframe: Day 0 to Day 7

Complete Response Rate (Complete Response and Complete Response Unconfirmed) Defined as Disappearance of All Evidence of Disease Based on Radiographic Findings on CT or MRI .

Intervention	mg*h/mL (Number)
Alpha-1 MP	155.9
Prolastin	152.4

(NCT00389818)
Timeframe: After cycles 2, 4, 6, 1 month after treatment discontinuation, every 2 months for 1 year after treatment discontinuation, every 6 months during the second and third years after treatment discontinuation

Article	Year
Biomaterial investigations in dentistry, 2021, Volume: 8, Issue:1 Topics: Adult; Alcohol Drinking; Ammonia; Animals; Anti-Inflammatory Agents; Area Under Curve; B-Lymphocytes	2021
Haemophagocytic lymphohistiocytosis associated with bartonella peliosis hepatis following kidney transplantation in a patient with HIV. The Lancet. Infectious diseases, 2022, Volume: 22, Issue:10 Topics: Angiomatosis, Bacillary; Animals; Bartonella; Bartonella henselae; Bartonella Infections; Dogs; Doxy	2022
Patient characteristics and outcome of CD20-positive HIV-associated lymphoma: a single-center KwaZulu-Natal, South African hospital 12-year retrospective review. Journal of the Egyptian National Cancer Institute, 2022, Aug-01, Volume: 34, Issue:1 Topics: Adult; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Cyclo	2022
Coronavirus disease 2019 in an orthotopic liver transplant recipient living with human immunodeficiency virus. Transplant infectious disease : an official journal of the Transplantation Society, 2020, Volume: 22, Issue:5 Topics: Adult; Anti-HIV Agents; Chemical and Drug Induced Liver Injury; COVID-19; COVID-19 Drug Treatment; D	2020
Clinical Features of HIV Arthropathy in Children: A Case Series and Literature Review. Frontiers in immunology, 2021, Volume: 12 Topics: Anti-HIV Agents; Anti-Inflammatory Agents, Non-Steroidal; Antirheumatic Agents; Arthritis; CD4 Lymph	2021
Treatment factors affecting outcomes in HIV-associated non-Hodgkin lymphomas: a pooled analysis of 1546 patients. Blood, 2013, Nov-07, Volume: 122, Issue:19 Topics: Anti-HIV Agents; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Agents; Antineoplastic Combi	2013
Case report and review of immunodeficiency-associated Burkitt lymphoma. Clinical lymphoma, myeloma & leukemia, 2015, Volume: 15, Issue:6 Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Burkitt Lymphoma; Cyclophosphamide; Doxorubic	2015
Dermatomyositis and HIV infection: case report and review of the literature. Rheumatology international, 2011, Volume: 31, Issue:5 Topics: Adult; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Autoimmunity; Biopsy; Dermatomyositis	2011
Pulmonary manifestations of the immune reconstitution inflammatory syndrome. Current opinion in pulmonary medicine, 2011, Volume: 17, Issue:3 Topics: Anti-Retroviral Agents; Glucocorticoids; HIV Infections; Humans; Immune Reconstitution Inflammatory	2011
Complete response to EPOCH in a patient with HIV and extracavitary primary effusion lymphoma involving the colon: a case report and review of literature. Clinical lymphoma, myeloma & leukemia, 2012, Volume: 12, Issue:2 Topics: Antineoplastic Combined Chemotherapy Protocols; Colonic Neoplasms; Cyclophosphamide; Doxorubicin; Et	2012
Rituximab in combination with chemotherapy versus chemotherapy alone in HIV-associated non-Hodgkin lymphoma: a pooled analysis of 15 prospective studies. American journal of hematology, 2012, Volume: 87, Issue:3 Topics: Adult; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Antir	2012
AIDS-related non-Hodgkin lymphoma: still a problem in the era of HAART. The AIDS reader, 2004, Volume: 14, Issue:11 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Antiretroviral Thera	2004
Primary effusion lymphoma. The oncologist, 2007, Volume: 12, Issue:5 Topics: Anti-Retroviral Agents; Antineoplastic Combined Chemotherapy Protocols; Ascitic Fluid; Cyclophospham	2007
Human immunodeficiency virus associated Hodgkin's disease: report of 45 cases from the French Registry of HIV-Associated Tumors. Leukemia & lymphoma, 1995, Volume: 16, Issue:5-6 Topics: Adult; AIDS-Related Opportunistic Infections; Antineoplastic Combined Chemotherapy Protocols; Bleomy	1995
Ocular syphilis and neurosyphilis in a patient with human immunodeficiency virus infection. Maryland medical journal (Baltimore, Md. : 1985), 1995, Volume: 44, Issue:4 Topics: Adult; Angiography; Drug Therapy, Combination; Eye Diseases; HIV Infections; Humans; Male; Neurosyph	1995
Effect of corticosteroid therapy on human immunodeficiency virus-associated nephropathy. The American journal of medicine, 1994, Volume: 97, Issue:2 Topics: Adult; Drug Administration Schedule; Female; HIV Infections; Humans; Kidney; Kidney Diseases; Male;	1994
HIV-associated Hodgkin's disease. International journal of STD & AIDS, 2000, Volume: 11, Issue:8 Topics: Antineoplastic Combined Chemotherapy Protocols; Antiretroviral Therapy, Highly Active; CD4 Lymphocyt	2000
Hodgkin's disease: clinical presentation and treatment. Cancer treatment and research, 2001, Volume: 104 Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Clinical Trials as Topic; Combined	2001
Neuropathies and myopathies complicating HIV infection. Journal of clinical apheresis, 1991, Volume: 6, Issue:2 Topics: Acquired Immunodeficiency Syndrome; Action Potentials; Adult; Antiviral Agents; Azathioprine; Combin	1991

Article	Year
In situ BCL2 expression is an independent prognostic factor in HIV-associated DLBCL, a LYMPHOVIR cohort study. British journal of haematology, 2020, Volume: 188, Issue:3 Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Disease-Free Survival; Doxo	2020
Response-adapted therapy with infusional EPOCH chemotherapy plus rituximab in HIV-associated, B-cell non-Hodgkin's lymphoma. Haematologica, 2021, 03-01, Volume: 106, Issue:3 Topics: Antineoplastic Combined Chemotherapy Protocols; B-Lymphocytes; Cyclophosphamide; Doxorubicin; Etopos	2021
Impact of Myc in HIV-associated non-Hodgkin lymphomas treated with EPOCH and outcomes with vorinostat (AMC-075 trial). Blood, 2020, 09-10, Volume: 136, Issue:11 Topics: Adult; Aged; Anti-HIV Agents; Antineoplastic Combined Chemotherapy Protocols; CD4 Lymphocyte Count;	2020
Population-based outcome analysis of diffuse large B-cell lymphoma in people living with HIV infection and competent individuals. Hematological oncology, 2018, Volume: 36, Issue:5 Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Murine-Derived; Antineoplastic C	2018
Prednisone for the Prevention of Paradoxical Tuberculosis-Associated IRIS. The New England journal of medicine, 2018, 11-15, Volume: 379, Issue:20 Topics: Adult; AIDS-Related Opportunistic Infections; Anti-Inflammatory Agents; Anti-Retroviral Agents; Anti	2018
Adjunctive corticosteroid treatment of clinical Pneumocystis jiroveci pneumonia in infants less than 18 months of age--a randomised controlled trial. South African medical journal = Suid-Afrikaanse tydskrif vir geneeskunde, 2008, Volume: 98, Issue:4 Topics: Age Factors; Anti-Infective Agents; Double-Blind Method; Drug Therapy, Combination; Female; Glucocor	2008
Randomized placebo-controlled trial of prednisone for paradoxical tuberculosis-associated immune reconstitution inflammatory syndrome. AIDS (London, England), 2010, Sep-24, Volume: 24, Issue:15 Topics: Adult; Antiretroviral Therapy, Highly Active; CD4 Lymphocyte Count; Double-Blind Method; Glucocortic	2010
Randomized placebo-controlled trial of prednisone for paradoxical tuberculosis-associated immune reconstitution inflammatory syndrome. AIDS (London, England), 2010, Sep-24, Volume: 24, Issue:15 Topics: Adult; Antiretroviral Therapy, Highly Active; CD4 Lymphocyte Count; Double-Blind Method; Glucocortic	2010
Randomized placebo-controlled trial of prednisone for paradoxical tuberculosis-associated immune reconstitution inflammatory syndrome. AIDS (London, England), 2010, Sep-24, Volume: 24, Issue:15 Topics: Adult; Antiretroviral Therapy, Highly Active; CD4 Lymphocyte Count; Double-Blind Method; Glucocortic	2010
Randomized placebo-controlled trial of prednisone for paradoxical tuberculosis-associated immune reconstitution inflammatory syndrome. AIDS (London, England), 2010, Sep-24, Volume: 24, Issue:15 Topics: Adult; Antiretroviral Therapy, Highly Active; CD4 Lymphocyte Count; Double-Blind Method; Glucocortic	2010
Pharmacokinetic comparability of Prolastin®-C to Prolastin® in alpha₁-antitrypsin deficiency: a randomized study. BMC clinical pharmacology, 2010, Sep-30, Volume: 10 Topics: alpha 1-Antitrypsin; alpha 1-Antitrypsin Deficiency; Antineoplastic Combined Chemotherapy Protocols;	2010
Long-term follow-up of patients with HIV-related diffuse large B-cell lymphomas treated in a phase II study with rituximab and CHOP. British journal of haematology, 2012, Volume: 157, Issue:5 Topics: Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Cyclophospha	2012
Corticosteroid-modulated immune activation in the tuberculosis immune reconstitution inflammatory syndrome. American journal of respiratory and critical care medicine, 2012, Aug-15, Volume: 186, Issue:4 Topics: Adult; Enzyme-Linked Immunospot Assay; Female; Follow-Up Studies; Glucocorticoids; HIV Infections; H	2012
Stage-adapted treatment of HIV-associated Hodgkin lymphoma: results of a prospective multicenter study. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2012, Nov-20, Volume: 30, Issue:33 Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Combined Modalit	2012
Pegylated liposomal doxorubicin, rituximab, cyclophosphamide, vincristine, and prednisone in AIDS-related lymphoma: AIDS Malignancy Consortium Study 047. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2013, Jan-01, Volume: 31, Issue:1 Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chem	2013
Stanford V regimen and concomitant HAART in 59 patients with Hodgkin disease and HIV infection. Blood, 2002, Sep-15, Volume: 100, Issue:6 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Antiretroviral Therapy, Highly Active;	2002
Randomized, controlled study of the effects of a short course of prednisone on the incidence of rash associated with nevirapine in patients infected with HIV-1. Journal of acquired immune deficiency syndromes (1999), 2003, May-01, Volume: 33, Issue:1 Topics: CD4 Lymphocyte Count; Drug Administration Schedule; Exanthema; Female; HIV; HIV Infections; Humans;	2003
A randomized, double-blinded, placebo-controlled trial of intermittent administration of interleukin-2 and prednisone in subjects infected with human immunodeficiency virus. The Journal of infectious diseases, 2003, Aug-15, Volume: 188, Issue:4 Topics: Anti-HIV Agents; Antiretroviral Therapy, Highly Active; CD4 Lymphocyte Count; CD4-Positive T-Lymphoc	2003
BEACOPP therapeutic regimen for patients with Hodgkin's disease and HIV infection. Annals of oncology : official journal of the European Society for Medical Oncology, 2003, Volume: 14, Issue:10 Topics: Adult; AIDS-Related Opportunistic Infections; Antineoplastic Combined Chemotherapy Protocols; Bleomy	2003
Intensive sequential chemotherapy with hematopoietic growth factor support for non-Hodgkin lymphoma in patients infected with the human immunodeficiency virus. Cancer, 2004, Feb-15, Volume: 100, Issue:4 Topics: Adult; Anti-HIV Agents; Antineoplastic Combined Chemotherapy Protocols; CD4 Lymphocyte Count; Cyclop	2004
Effect of highly active antiretroviral therapy (HAART) on pharmacokinetics and pharmacodynamics of doxorubicin in patients with HIV-associated non-Hodgkin's lymphoma. Annals of oncology : official journal of the European Society for Medical Oncology, 2004, Volume: 15, Issue:12 Topics: Adult; Antibiotics, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Antiretroviral T	2004
Human immunodeficiency virus associated Hodgkin's disease: report of 45 cases from the French Registry of HIV-Associated Tumors. Leukemia & lymphoma, 1995, Volume: 16, Issue:5-6 Topics: Adult; AIDS-Related Opportunistic Infections; Antineoplastic Combined Chemotherapy Protocols; Bleomy	1995
Comparison of two corticosteroid regimens for the treatment of HIV-associated idiopathic esophageal ulcer. The American journal of gastroenterology, 1994, Volume: 89, Issue:12 Topics: Adult; Drug Administration Schedule; Esophageal Diseases; Female; HIV Infections; Humans; Male; Pred	1994
Prednisone therapy is not associated with increased risk of herpetic infections in patients infected with human immunodeficiency virus. Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 1996, Volume: 23, Issue:1 Topics: AIDS-Related Opportunistic Infections; CD4 Lymphocyte Count; Chickenpox; Cytomegalovirus Infections;	1996
[Colony-stimulating factors and HIV-related neoplasms]. Anales de medicina interna (Madrid, Spain : 1984), 1996, Volume: 13, Issue:7 Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Blood Cell Count; Cyclophosphamide	1996
Stanford V regimen and concomitant highly active antiretroviral therapy is feasible and active in patients with Hodgkin's disease and HIV infection. AIDS (London, England), 2000, Jul-07, Volume: 14, Issue:10 Topics: Adult; Anti-HIV Agents; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Doxorubicin; Etop	2000
Prevention of nevirapine-associated exanthema using slow dose escalation and/or corticosteroids. AIDS (London, England), 2000, Sep-29, Volume: 14, Issue:14 Topics: Anti-HIV Agents; Anti-Inflammatory Agents; Exanthema; HIV Infections; Humans; Nevirapine; Prednisone	2000
Placebo-controlled trial of prednisone in advanced HIV-1 infection. AIDS (London, England), 2001, Feb-16, Volume: 15, Issue:3 Topics: Acquired Immunodeficiency Syndrome; Adult; Anti-HIV Agents; Anti-Inflammatory Agents; CD4 Lymphocyte	2001
Chemotherapy for human immunodeficiency virus-associated non-Hodgkin's lymphoma in combination with highly active antiretroviral therapy. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2001, Apr-15, Volume: 19, Issue:8 Topics: Adult; Anti-HIV Agents; Antineoplastic Combined Chemotherapy Protocols; Antiretroviral Therapy, High	2001
[Malignant lymphoma associated with HIV infection]. Deutsche medizinische Wochenschrift (1946), 1991, Aug-16, Volume: 116, Issue:33 Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Combined Modalit	1991
Clinical and virologic effects of recombinant human granulocyte-macrophage colony-stimulating factor in patients receiving chemotherapy for human immunodeficiency virus-associated non-Hodgkin's lymphoma: results of a randomized trial. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 1991, Volume: 9, Issue:6 Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Cyclophosphamide	1991

Article	Year
Primary chest wall Burkitt lymphoma in a case of HIV infection with immune reconstitution. BMJ case reports, 2021, Dec-30, Volume: 14, Issue:12 Topics: Antineoplastic Combined Chemotherapy Protocols; Burkitt Lymphoma; Cyclophosphamide; Doxorubicin; Eto	2021
HIV-associated plasmablastic lymphoma: A single-centre 12-year experience in Kwa-Zulu Natal, South Africa. HIV medicine, 2022, Volume: 23, Issue:8 Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Doxorubicin; Fe	2022
Safety and efficacy of a dose-dense short-term therapy in patients with MYC-translocated aggressive lymphoma. Blood advances, 2022, 11-22, Volume: 6, Issue:22 Topics: Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Burkitt Lymp	2022
Diffuse Large B-Cell Lymphoma in Chile: The Impact of Combined CHOP Plus Rituximab in the Public Health System. JCO global oncology, 2022, Volume: 8 Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chile; C	2022
Primary esophageal diffuse large B-cell lymphoma. Revista espanola de enfermedades digestivas, 2023, Volume: 115, Issue:7 Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Diabetes Mellitus, Type 2; D	2023
The prognostic impact of monocyte fluorescence, immunosuppressive monocytes and peripheral blood immune cell numbers in HIV-associated Diffuse Large B-cell Lymphoma. PloS one, 2023, Volume: 18, Issue:1 Topics: Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Fluorescence	2023
Diffuse Large B-Cell Lymphoma Treated With R-CHOP in a Resource-Limited Setting in South Africa: A Real-World Study. The oncologist, 2023, 09-07, Volume: 28, Issue:9 Topics: Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Doxorubicin; Female; HIV Infection	2023
Different clinical phenotypes of AQP4-IgG positive NMOSD in two first degree relatives. BMC neurology, 2023, Sep-04, Volume: 23, Issue:1 Topics: Adult; Autoimmune Diseases; Azathioprine; Female; Gadolinium; HIV Infections; Humans; Immunoglobulin	2023
Improved survival of children and adolescents with classical Hodgkin lymphoma treated on a harmonised protocol in South Africa. Pediatric blood & cancer, 2024, Volume: 71, Issue:1 Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Child; Dacarbazine; Doxorubic	2024
Modified EPOCH for high-risk non-Hodgkin lymphoma in sub-Saharan Africa. Cancer medicine, 2020, Volume: 9, Issue:1 Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; CD4 Lymphocyte Count; Cyclophosph	2020
A Rare Case of Diffuse Large B Cell Lymphoma Presenting as a Cardiac Mass. The American journal of case reports, 2019, Dec-06, Volume: 20 Topics: Antineoplastic Combined Chemotherapy Protocols; Antiretroviral Therapy, Highly Active; Cough; Cyclop	2019
The effect of HIV-associated tuberculosis, tuberculosis-IRIS and prednisone on lung function. The European respiratory journal, 2020, Volume: 55, Issue:3 Topics: HIV Infections; Humans; Immune Reconstitution Inflammatory Syndrome; Lung; Prednisone; Tuberculosis	2020
Case Report: A Case of Severe Cryptococcal Immune Reconstitution Inflammatory Syndrome Presenting with Brain and Intradural Abscesses in an HIV Patient. The American journal of tropical medicine and hygiene, 2020, Volume: 103, Issue:2 Topics: Acquired Immunodeficiency Syndrome; Amphotericin B; Anti-Inflammatory Agents; Anti-Retroviral Agents	2020
The Early Results of Vertebral Pathological Compression Fracture of Extra- nodal Lymphoma with HIV-positive Patients Treated by Percutaneous Kyphoplasty. Current HIV research, 2020, Volume: 18, Issue:4 Topics: Adult; Alkynes; Antineoplastic Combined Chemotherapy Protocols; Antiretroviral Therapy, Highly Activ	2020
The effectiveness of rituximab and HIV on the survival of Ontario patients with diffuse large B-cell lymphoma. Cancer medicine, 2020, Volume: 9, Issue:19 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Da	2020
Outcomes of treatment with CHOP and EPOCH in patients with HIV associated NHL in a low resource setting. BMC cancer, 2020, Aug-24, Volume: 20, Issue:1 Topics: Adult; Anemia; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Doxorubicin; Drug A	2020
Clinical outcomes of people living with human immunodeficiency virus (HIV) with diffuse large B-cell lymphoma (DLBCL) in Shanghai, China. Chinese medical journal, 2020, Dec-05, Volume: 133, Issue:23 Topics: Antineoplastic Combined Chemotherapy Protocols; China; Cyclophosphamide; Doxorubicin; HIV; HIV Infec	2020
A tip of the iceberg: Disseminated plasmablastic lymphoma, diagnosed from a local oral lesion. The Kaohsiung journal of medical sciences, 2021, Volume: 37, Issue:4 Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Antiretroviral Therapy, Highly Active; Biopsy	2021
[Diagnosis and treatment of HIV-associated lymphoma: Update 202]. Deutsche medizinische Wochenschrift (1946), 2021, Volume: 146, Issue:11 Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Doxorubicin	2021
HIV-negative plasmablastic lymphoma attaining sustained remission with bortezomib-combined dose-adjusted EPOCH therapy. [Rinsho ketsueki] The Japanese journal of clinical hematology, 2017, Volume: 58, Issue:5 Topics: Antineoplastic Combined Chemotherapy Protocols; Bortezomib; Cyclophosphamide; Doxorubicin; Etoposide	2017
A rare occurrence of epidermolysis bullosa acquisita in a patient with retroviral disease. International journal of STD & AIDS, 2017, Volume: 28, Issue:12 Topics: Adult; Autoimmune Diseases; Autoimmunity; Cyclophosphamide; Epidermolysis Bullosa Acquisita; Female;	2017
Nodular granulomatous Pneumocystis jiroveci pneumonia consequent to delayed immune reconstitution inflammatory syndrome. International journal of STD & AIDS, 2018, Volume: 29, Issue:14 Topics: Adult; Anti-Infective Agents, Urinary; Antiretroviral Therapy, Highly Active; Bronchoscopy; Female;	2018
The tuberculosis-associated immune reconstitution inflammatory syndrome: recent advances in clinical and pathogenesis research. Current opinion in HIV and AIDS, 2018, Volume: 13, Issue:6 Topics: Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Antitubercular Agents; HIV Infections; Human	2018
Impact of HIV Infection on the Clinical Presentation and Survival of Non-Hodgkin Lymphoma: A Prospective Observational Study From Botswana. Journal of global oncology, 2018, Volume: 4 Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Antiretroviral Therapy, Highly Ac	2018
[Clinicopathological Characteristics and Prognosis Analysis of the Patients with Plasmablastic Lymphoma]. Zhongguo shi yan xue ye xue za zhi, 2018, Volume: 26, Issue:5 Topics: Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Doxorubicin; Etoposide; Female; HI	2018
Progressive multifocal leukoencephalopathy unmasked by antiretroviral therapy for HIV. CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne, 2018, 10-22, Volume: 190, Issue:42 Topics: Anti-Retroviral Agents; Disease Progression; Glucocorticoids; HIV Infections; Humans; Immune Reconst	2018
Different effects of glucocorticoids on darunavir plasma concentrations. European journal of clinical pharmacology, 2019, Volume: 75, Issue:5 Topics: Cytochrome P-450 CYP3A; Darunavir; Drug Combinations; Drug Interactions; Glucocorticoids; HIV Infect	2019
Prospective study of Burkitt lymphoma treatment in adolescents and adults in Malawi. Blood advances, 2019, 02-26, Volume: 3, Issue:4 Topics: Adolescent; Adult; Anti-Retroviral Agents; Antineoplastic Combined Chemotherapy Protocols; Burkitt L	2019
IgG4-related disease in a patient with HIV infection. BMJ case reports, 2019, Apr-14, Volume: 12, Issue:4 Topics: Azathioprine; Dyspnea; Glucocorticoids; HIV Infections; Humans; Immunoglobulin G; Immunoglobulin G4-	2019
Immune reconstitution inflammatory syndrome in an HIV-infected patient with disseminated coccidioidomycosis. International journal of STD & AIDS, 2019, Volume: 30, Issue:9 Topics: Adult; AIDS-Related Opportunistic Infections; Anti-HIV Agents; Antifungal Agents; Antiretroviral The	2019
Safety and efficacy of CHOP for treatment of diffuse large B-cell lymphoma with different combination antiretroviral therapy regimens: SCULPT study. Antiviral therapy, 2013, Volume: 18, Issue:5 Topics: Adult; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Antiretroviral Therapy	2013
AIDS-lymphoma (ARL): one more step along the way. Blood, 2013, Nov-07, Volume: 122, Issue:19 Topics: Anti-HIV Agents; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Agents; Antineoplastic Combi	2013
Successful treatment of histiocytic sarcoma and concurrent HIV infection using a combination of CHOP and antiretroviral therapy. Internal medicine (Tokyo, Japan), 2013, Volume: 52, Issue:24 Topics: Antineoplastic Combined Chemotherapy Protocols; Antiretroviral Therapy, Highly Active; Bone Marrow C	2013
HIV status does not impair the outcome of patients diagnosed with diffuse large B-cell lymphoma treated with R-CHOP in the cART era. AIDS (London, England), 2014, Mar-13, Volume: 28, Issue:5 Topics: Adolescent; Adult; Aged; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherap	2014
Ostraceous and inverse psoriasis with psoriatic arthritis as the presenting features of advanced HIV infection. Singapore medical journal, 2014, Volume: 55, Issue:4 Topics: Administration, Oral; Adult; Arthritis, Psoriatic; Biopsy; Diagnosis, Differential; HIV Infections;	2014
Management of refractory telaprevir-induced dermatitis using oral corticosteroids. Actas dermo-sifiliograficas, 2014, Volume: 105, Issue:9 Topics: Administration, Oral; Aged; Anti-Inflammatory Agents; Antiviral Agents; Drug Eruptions; Drug Therapy	2014
Therapy of HIV-associated lymphoma-recommendations of the oncology working group of the German Study Group of Physicians in Private Practice Treating HIV-Infected Patients (DAGNÄ), in cooperation with the German AIDS Society (DAIG). Annals of hematology, 2014, Volume: 93, Issue:6 Topics: Anti-HIV Agents; Antibiotic Prophylaxis; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Comb	2014
Etravirine: a good option for concomitant use with chemotherapy for Hodgkin's lymphoma. International journal of STD & AIDS, 2015, Volume: 26, Issue:3 Topics: Antineoplastic Combined Chemotherapy Protocols; Biopsy; Bleomycin; Cyclophosphamide; Doxorubicin; Et	2015
HIV-infection impact on clinical-biological features and outcome of diffuse large B-cell lymphoma treated with R-CHOP in the combination antiretroviral therapy era. AIDS (London, England), 2015, Apr-24, Volume: 29, Issue:7 Topics: Adult; Aged; Aged, 80 and over; Anti-Retroviral Agents; Antibodies, Monoclonal, Murine-Derived; Anti	2015
Isolated and bilateral simultaneous facial palsy disclosing early human immunodeficiency virus infection. Singapore medical journal, 2015, Volume: 56, Issue:6 Topics: Administration, Oral; Cerebrospinal Fluid Pressure; Enzyme-Linked Immunosorbent Assay; Facial Paraly	2015
CHOP Chemotherapy for Aggressive Non-Hodgkin Lymphoma with and without HIV in the Antiretroviral Therapy Era in Malawi. PloS one, 2016, Volume: 11, Issue:3 Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Antirheumatic Agents; Cyclophosphamide; Doxor	2016
Guidelines for the management of diffuse large B-cell lymphoma. British journal of haematology, 2016, Volume: 174, Issue:1 Topics: Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Cyclophospha	2016
Aggressive extensive cardiac mass in an HIV-1-infected patient: should we go for comfort therapy? Acta clinica Belgica, 2017, Volume: 72, Issue:3 Topics: Anti-HIV Agents; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protoc	2017
Plasmablastic lymphoma: an atypical cutaneous presentation of a rare entity. Dermatology online journal, 2016, May-15, Volume: 22, Issue:5 Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Antiretroviral Therapy, Highly Active; Cycloph	2016
Moderating effects of immunosuppressive medications and risk factors for post-operative joint infection following total joint arthroplasty in patients with rheumatoid arthritis or osteoarthritis. Seminars in arthritis and rheumatism, 2017, Volume: 46, Issue:4 Topics: Aged; Allopurinol; Arthritis, Rheumatoid; Arthroplasty, Replacement; Arthroplasty, Replacement, Hip;	2017
[Clinical features and outcomes: analysis of 9 cases of HIV-negtive plasmablastic lymphoma]. Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi, 2016, Sep-14, Volume: 37, Issue:9 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Disease-Free Survival	2016
Primary Maxillary Sinus Plasmablastic Lymphoma in HIV/AIDS. The Journal of the Association of Physicians of India, 2016, Volume: 64, Issue:5 Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Biopsy; Cyclophosphamide; Doxorubicin; HIV In	2016
Autoimmune hepatitis in patients with human immunodeficiency virus (HIV): Case reports of a rare, but important diagnosis with therapeutic implications. Medicine, 2017, Volume: 96, Issue:7 Topics: Adult; Anti-Inflammatory Agents; Azathioprine; Female; Hepatitis, Autoimmune; HIV Infections; Humans	2017
Diffuse large B-cell lymphoma presenting as multiple lymphomatous polyposis of the gastrointestinal tract. Clinical lymphoma & myeloma, 2008, Volume: 8, Issue:3 Topics: Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Diagnosis, Differential; Doxorubic	2008
Successful treatment of aggressive HIV-associated multicentric Castleman's disease: a case report. WMJ : official publication of the State Medical Society of Wisconsin, 2008, Volume: 107, Issue:4 Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy	2008
Opsoclonus-myoclonus syndrome and HIV-infection. Journal of the neurological sciences, 2009, Sep-15, Volume: 284, Issue:1-2 Topics: Adult; Alkynes; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Antitubercular Agents; Autoi	2009
Is cytotoxic chemotherapy for lymphoma currently feasible for patients in Malawi? A debate. Malawi medical journal : the journal of Medical Association of Malawi, 2008, Volume: 20, Issue:4 Topics: Adult; Anti-Retroviral Agents; Antineoplastic Combined Chemotherapy Protocols; Antiretroviral Therap	2008
Temporal artery vasculitis in young: a report of two cases. Rheumatology international, 2010, Volume: 30, Issue:10 Topics: Adult; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Giant Cell Arteritis; HIV Infections;	2010
Tegumentary leishmaniasis as the cause of immune reconstitution inflammatory syndrome in a patient co-infected with human immunodeficiency virus and Leishmania guyanensis. The American journal of tropical medicine and hygiene, 2009, Volume: 81, Issue:4 Topics: Adult; Animals; Anti-Infective Agents; Anti-Inflammatory Agents; Antiretroviral Therapy, Highly Acti	2009
Orbital plasmablastic lymphoma--comparison of a newly reported entity with diffuse large B-cell lymphoma of the orbit. Orbit (Amsterdam, Netherlands), 2009, Volume: 28, Issue:6 Topics: Adult; Antigens, CD; Antineoplastic Combined Chemotherapy Protocols; Antiretroviral Therapy, Highly	2009
Complex regional pain syndrome in a HIV seropositive patient starting antiretroviral therapy. Journal of clinical rheumatology : practical reports on rheumatic & musculoskeletal diseases, 2009, Volume: 15, Issue:7 Topics: Adult; Anti-Inflammatory Agents; Anti-Retroviral Agents; Female; HIV Infections; Humans; Physical Th	2009
Prognostic factors in chemotherapy-treated patients with HIV-associated Plasmablastic lymphoma. The oncologist, 2010, Volume: 15, Issue:3 Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Child; Child, Preschool; Cyclopho	2010
Febrile neutropenia in a HIV positive individual post-chemotherapy. Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology, 2010, Volume: 48, Issue:1 Topics: Antineoplastic Combined Chemotherapy Protocols; Antiviral Agents; Cyclophosphamide; Cytomegalovirus	2010
Immune thrombocytopaenia in adults: a single-centre retrospective review of patients presenting over 7 years. The New Zealand medical journal, 2010, Apr-09, Volume: 123, Issue:1312 Topics: Adult; Antibodies, Antinuclear; Antineoplastic Agents, Phytogenic; Azathioprine; Biopsy, Fine-Needle	2010
[Bilateral optic neuropathy in an HIV patient]. Neurologia (Barcelona, Spain), 2010, Volume: 25, Issue:4 Topics: Adult; Anti-Inflammatory Agents; Diagnosis, Differential; HIV Infections; Humans; Male; Optic Nerve	2010
Polymyositis in African HIV-infected subjects. Neuromuscular disorders : NMD, 2010, Volume: 20, Issue:11 Topics: Adult; Anti-Inflammatory Agents; Black People; Creatine Kinase; Female; HIV Infections; Humans; Midd	2010
Hypercytokinaemia accompanies HIV-tuberculosis immune reconstitution inflammatory syndrome. The European respiratory journal, 2011, Volume: 37, Issue:5 Topics: Adult; Antiretroviral Therapy, Highly Active; Case-Control Studies; CD4-Positive T-Lymphocytes; Cell	2011
Acute fibrinous and organizing pneumonia in a patient with HIV infection and Pneumocystis jiroveci pneumonia. Respirology (Carlton, Vic.), 2010, Volume: 15, Issue:8 Topics: Acute Disease; Adult; AIDS-Related Opportunistic Infections; Cryptogenic Organizing Pneumonia; Diagn	2010
Unusual presentation of gastric plasmablastic lymphoma in HIV-negative patient. Medical oncology (Northwood, London, England), 2012, Volume: 29, Issue:2 Topics: Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Doxorubicin; HIV; HIV Infections;	2012
Positive HIV ELISA test, autoimmune hemolytic anemia, and generalized lymphadenopathy: a unifying diagnosis. American journal of hematology, 2011, Volume: 86, Issue:8 Topics: Adult; Anemia, Hemolytic, Autoimmune; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Agents;	2011
Human immunodeficiency virus-associated Burkitt's lymphoma in oral cavity of Japanese patient. Journal of oral and maxillofacial surgery : official journal of the American Association of Oral and Maxillofacial Surgeons, 2012, Volume: 70, Issue:8 Topics: Antibiotics, Antineoplastic; Antineoplastic Agents, Alkylating; Antineoplastic Agents, Hormonal; Ant	2012
Immune reconstitution renal-limited sarcoidosis presenting as acute kidney injury. International journal of STD & AIDS, 2012, Volume: 23, Issue:1 Topics: Acute Kidney Injury; Adenine; Adult; AIDS-Associated Nephropathy; Anti-Retroviral Agents; Atazanavir	2012
Orbital plasmablastic lymphoma with remission following chemotherapy. Journal of radiology case reports, 2011, Volume: 5, Issue:2 Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Doxorubicin; Etoposide; Fil	2011
Cutaneous CD8+ T-cell infiltrates associated with human immunodeficiency virus. Actas dermo-sifiliograficas, 2012, Volume: 103, Issue:7 Topics: Adenine; Alopecia; Anti-HIV Agents; Antigens, Differentiation, T-Lymphocyte; Antiretroviral Therapy,	2012
Incidence, predictors and significance of severe toxicity in patients with human immunodeficiency virus-associated Hodgkin lymphoma. Leukemia & lymphoma, 2012, Volume: 53, Issue:12 Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Antiretroviral Therapy, Highly Active; Bleomy	2012
Paying more than lip service to an oral lesion: a case of plasmablastic lymphoma. BMJ case reports, 2012, Jul-13, Volume: 2012 Topics: Administration, Inhalation; Adrenal Cortex Hormones; Adult; Antineoplastic Combined Chemotherapy Pro	2012
A retrospective, multi-center analysis of treatment intensification for human immunodeficiency virus-positive patients with high-risk diffuse large B-cell lymphoma. Leukemia & lymphoma, 2013, Volume: 54, Issue:9 Topics: Adult; Aged; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols;	2013
Tuberculosis and immune thrombocytopenia. Haematologica, 2002, Volume: 87, Issue:8 Topics: Adrenal Cortex Hormones; Antineoplastic Combined Chemotherapy Protocols; Antitubercular Agents; Aspa	2002
Nevirapine, prednisone and rash. Project Inform perspective, 2000, Issue:31 Topics: Diphenhydramine; Exanthema; HIV Infections; Humans; Nevirapine; Prednisone	2000
Immune reconstitution during intensive chemotherapy in patients with human immunodeficiency virus related non-Hodgkin lymphoma. The hematology journal : the official journal of the European Haematology Association, 2002, Volume: 3, Issue:4 Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; CD4 Lymphocyte Count; Combined Modality Thera	2002
Hypersensitivity to efavirenz treated with corticosteroids in a 6-year-old child. AIDS patient care and STDs, 2003, Volume: 17, Issue:1 Topics: Alkynes; Anti-HIV Agents; Benzoxazines; Child; Cyclopropanes; Drug Administration Schedule; Female;	2003
Impact of concomitant antiblastic chemotherapy and highly active antiretroviral therapy on human immunodeficiency virus (HIV) viremia and genotyping in HIV-infected patients with non-Hodgkin lymphoma. Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2003, Sep-15, Volume: 37, Issue:6 Topics: Adolescent; Adult; Anti-HIV Agents; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived;	2003
Case records of the Massachusetts General Hospital. Weekly clinicopathological exercises. Case 31-2003. A 44-year-old man with HIV infection and a right atrial mass. The New England journal of medicine, 2003, Oct-02, Volume: 349, Issue:14 Topics: Adult; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemo	2003
Clinical features and outcome of primary effusion lymphoma in HIV-infected patients: a single-institution study. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2003, Nov-01, Volume: 21, Issue:21 Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Antiretroviral Therapy, Highly Active; Cyclop	2003
[Multiple myeloma and HIV infection: report of 3 cases]. Revue medicale de Liege, 2004, Volume: 59, Issue:2 Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Female; HIV Infections; Hum	2004
Postinfectious diffuse proliferative glomerulonephritis and acute renal failure in an HIV patient. Clinical nephrology, 2004, Volume: 61, Issue:4 Topics: Acute Kidney Injury; Adult; Biopsy; Female; Glomerulonephritis; Glucocorticoids; HIV Infections; Hum	2004
Progressive multifocal leukoencephalopathy after initiation of highly active antiretroviral therapy in a child with advanced human immunodeficiency virus infection: a case of immune reconstitution inflammatory syndrome. The Pediatric infectious disease journal, 2004, Volume: 23, Issue:7 Topics: Antiretroviral Therapy, Highly Active; Child; Glucocorticoids; HIV Infections; Humans; Leukoencephal	2004
Painful neuropathy vasculitis in 2 patients with long-standing human immunodeficiency virus-1 infection. Scandinavian journal of infectious diseases, 2004, Volume: 36, Issue:5 Topics: Adult; Antiretroviral Therapy, Highly Active; Follow-Up Studies; HIV Infections; HIV-1; Humans; Long	2004
Treatment of recurring cutaneous drug reactions in patients with human immunodeficiency virus 1 infection: a series of 3 cases. Archives of dermatology, 2004, Volume: 140, Issue:9 Topics: Adult; Antiretroviral Therapy, Highly Active; Dose-Response Relationship, Drug; Drug Administration	2004
Disseminated plasmablastic lymphoma. Journal of the American College of Surgeons, 2004, Volume: 199, Issue:4 Topics: Anti-HIV Agents; Antineoplastic Combined Chemotherapy Protocols; Antiretroviral Therapy, Highly Acti	2004
Relapsing polychondritis in HIV-infected patients: a report of two cases. Journal of the American Academy of Dermatology, 2004, Volume: 51, Issue:6 Topics: Adult; Anti-Inflammatory Agents; Dapsone; HIV Infections; Humans; Male; Polychondritis, Relapsing; P	2004
Pharmacokinetic interaction between chemotherapy for non-Hodgkin's lymphoma and protease inhibitors in HIV-1-infected patients. The Journal of antimicrobial chemotherapy, 2005, Volume: 55, Issue:4 Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Cross-Over Studies; Cycloph	2005
Metastatic Crohn's disease mimicking genital pyoderma gangrenosum in an HIV patient. Acta dermato-venereologica, 2005, Volume: 85, Issue:1 Topics: Adult; Anti-Infective Agents; Anti-Inflammatory Agents; Crohn Disease; Diagnosis, Differential; Gran	2005
The prognosis of HIV-infected patients with diffuse large B-cell lymphoma treated with chemotherapy and highly active antiretroviral therapy is similar to that of HIV-negative patients receiving chemotherapy. Haematologica, 2005, Volume: 90, Issue:5 Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Antiretroviral Therapy, Highly Active; Cyclop	2005
Epstein-Barr virus DNA in serum in a HIV-infected patient during development and treatment of non-Hodgkin's lymphoma. Swiss medical weekly, 2005, Apr-30, Volume: 135, Issue:17-18 Topics: Anti-HIV Agents; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; DNA, Viral; Doxor	2005
Coexistent sarcoidosis and HIV infection: an immunological paradox? The Journal of infection, 2006, Volume: 52, Issue:3 Topics: Adult; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Female; HIV Infections; Humans; Predn	2006
Current status of the treatment of HIV-associated lymphoma. Clinical advances in hematology & oncology : H&O, 2004, Volume: 2, Issue:1 Topics: Anti-HIV Agents; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Comb	2004
Anti-glomerular basement membrane glomerulonephritis in an HIV positive patient: case report. The Brazilian journal of infectious diseases : an official publication of the Brazilian Society of Infectious Diseases, 2006, Volume: 10, Issue:1 Topics: Adult; Anti-Glomerular Basement Membrane Disease; Antibodies; Antibodies, Antineutrophil Cytoplasmic	2006
Behçet's disease in an HIV-1-infected patient treated with highly active antiretroviral therapy. The Israel Medical Association journal : IMAJ, 2006, Volume: 8, Issue:7 Topics: Adult; Aged; Anti-Inflammatory Agents; Antiretroviral Therapy, Highly Active; Behcet Syndrome; Colch	2006
Treatment of HIV-associated Burkitt Lymphoma in the presence of severe hepatic dysfunction. Clinical advances in hematology & oncology : H&O, 2006, Volume: 4, Issue:11 Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Burkitt Lymphoma; Cyclophosphamide; Doxorubic	2006
Hodgkin lymphoma among patients infected with HIV in post-HAART era. Clinical lymphoma & myeloma, 2007, Volume: 7, Issue:5 Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Antiretroviral Therapy, Highly Active; Bleomy	2007
Recent thymic emigrants in lymphoma patients with and without human immunodeficiency virus infection candidates for autologous peripheral stem cell transplantation. Clinical and experimental immunology, 2008, Volume: 151, Issue:1 Topics: Adult; Age Factors; Aged; Aged, 80 and over; Anti-HIV Agents; Antineoplastic Combined Chemotherapy P	2008
Cutaneous plasmablastic lymphoma. Journal of the American Academy of Dermatology, 2008, Volume: 58, Issue:4 Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Cyclophosphamide; Doxorubicin; Etoposid	2008
Thrombocytopenia in the HIV-infected patient. Hospital practice (Office ed.), 1994, Aug-15, Volume: 29, Issue:8 Topics: Adult; Autoimmune Diseases; Danazol; gamma-Globulins; HIV Infections; Humans; Male; Prednisone; Recu	1994
Hodgkin's disease and non-Hodgkin's lymphoma in an HIV positive patient. Leukemia & lymphoma, 1993, Volume: 9, Issue:4-5 Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Child; Cyclophosphamide; Dexametha	1993
Sarcoid myopathy in a patient with human immunodeficiency virus infection. Southern medical journal, 1995, Volume: 88, Issue:5 Topics: Adult; CD4 Antigens; HIV Infections; Homosexuality, Male; Humans; Male; Muscular Diseases; Prednison	1995
Immunologic and virologic effects of glucocorticoids on human immunodeficiency virus infection in children: a preliminary study. The Pediatric infectious disease journal, 1994, Volume: 13, Issue:3 Topics: CD4-CD8 Ratio; CD4-Positive T-Lymphocytes; Child; Child, Preschool; HIV Core Protein p24; HIV Infect	1994
[Hemophagocytic syndrome in HIV infection]. Presse medicale (Paris, France : 1983), 1993, Sep-11, Volume: 22, Issue:26 Topics: Adult; Blood Transfusion; Female; Histiocytosis, Non-Langerhans-Cell; HIV Infections; Humans; Male;	1993
[Neuropathy caused by necrotizing vasculitis in HIV-1 infection]. Revue neurologique, 1993, Volume: 149, Issue:5 Topics: Adult; HIV Infections; HIV-1; Humans; Male; Peripheral Nervous System Diseases; Prednisone; Vasculit	1993
[Idiopathic esophageal ulcer cured with corticosteroids in a patient with HIV infection]. Enfermedades infecciosas y microbiologia clinica, 1993, Volume: 11, Issue:9 Topics: Adult; Esophageal Diseases; HIV Infections; Humans; Male; Prednisone; Remission Induction; Ulcer	1993
Endoscopic characterization of idiopathic esophageal ulceration associated with human immunodeficiency virus infection. Journal of clinical gastroenterology, 1993, Volume: 16, Issue:3 Topics: Adult; Deglutition Disorders; Esophageal Diseases; Esophagoscopy; Female; HIV Infections; Humans; Ma	1993
Prednisone improves renal function and proteinuria in human immunodeficiency virus-associated nephropathy. The American journal of medicine, 1996, Volume: 101, Issue:1 Topics: Adult; Aged; Creatinine; Female; Follow-Up Studies; Glucocorticoids; HIV Infections; Humans; Kidney	1996
The diffuse infiltrative lymphocytosis syndrome. Clinical and immunogenetic features in 35 patients. AIDS (London, England), 1996, Volume: 10, Issue:4 Topics: Adult; Amino Acid Sequence; Anti-Inflammatory Agents; Black People; Cohort Studies; Female; Genes, M	1996
[Effect of granulocyte colony-stimulating factor after chemotherapy with CHOP in patients with non-Hodgkin's lymphoma and HIV infection]. Medicina clinica, 1996, Jun-15, Volume: 107, Issue:3 Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Doxorubicin; Female; Granul	1996
Ramsay Hunt syndrome in a patient infected with human immunodeficiency virus. Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 1996, Volume: 22, Issue:6 Topics: 2-Aminopurine; Acyclovir; Adult; Famciclovir; Herpes Zoster Oticus; HIV Infections; Humans; Male; Pr	1996
Renal involvement in the diffuse infiltrative CD8 lymphocytosis syndrome. AIDS (London, England), 1997, Volume: 11, Issue:2 Topics: Adult; Anti-HIV Agents; CD8-Positive T-Lymphocytes; HIV Infections; Humans; Kidney Diseases; Lymphoc	1997
Resolution of HIV-associated cystic benign lymphoepithelial lesion of the parotid gland in a patient undergoing chemotherapy for non-Hodgkin's lymphoma. Scandinavian journal of infectious diseases, 1996, Volume: 28, Issue:6 Topics: Antineoplastic Combined Chemotherapy Protocols; Antiviral Agents; Cyclophosphamide; Cysts; Didanosin	1996
Reactivation of HIV type 1 in chronically infected chimpanzees following xenostimulation with human cells or with pulses of corticosteroid. AIDS research and human retroviruses, 1997, Mar-20, Volume: 13, Issue:5 Topics: Animals; DNA, Viral; HIV Antibodies; HIV Infections; HIV-1; Humans; Immunosuppressive Agents; Leukoc	1997
Prednisone, renal function, and proteinuria in immunodeficiency virus-associated nephropathy. American journal of kidney diseases : the official journal of the National Kidney Foundation, 1997, Volume: 30, Issue:1 Topics: Anti-Inflammatory Agents; HIV Infections; Humans; Kidney Diseases; Prednisone; Prospective Studies;	1997
Idiopathic colonic inflammation in AIDS: an open trial of prednisone. The American journal of gastroenterology, 1997, Volume: 92, Issue:12 Topics: Acquired Immunodeficiency Syndrome; Adult; Anti-Inflammatory Agents; Anus Diseases; Biopsy; Colectom	1997
Response of lymphoepithelial parotid cysts to antiretroviral treatment in HIV-infected adults. Annals of internal medicine, 1998, Mar-15, Volume: 128, Issue:6 Topics: Adult; Anti-HIV Agents; CD4 Lymphocyte Count; Chronic Disease; Cysts; Drug Therapy, Combination; Fem	1998
Use of adjunctive corticosteroids in severe adult non-HIV Pneumocystis carinii pneumonia. Chest, 1998, Volume: 113, Issue:5 Topics: Anti-Infective Agents; Antifungal Agents; Drug Therapy, Combination; Female; Glucocorticoids; HIV In	1998
Seronegative myasthenia gravis and human immunodeficiency virus infection: response to intravenous gamma globulin and prednisone. The Canadian journal of neurological sciences. Le journal canadien des sciences neurologiques, 1998, Volume: 25, Issue:3 Topics: Adult; Anti-Inflammatory Agents; Edrophonium; Electroencephalography; Electrophysiology; gamma-Globu	1998
Long-term nonprogressive human immunodeficiency virus-1 infection in a kidney allograft recipient. Transplantation, 1998, Nov-27, Volume: 66, Issue:10 Topics: Adult; Azathioprine; CD4 Lymphocyte Count; CD4-CD8 Ratio; CD4-Positive T-Lymphocytes; Female; Graft	1998
[Thrombotic thrombocytopenic purpura associated with HIV infection]. Anales de medicina interna (Madrid, Spain : 1984), 1999, Volume: 16, Issue:4 Topics: Adult; Anti-Inflammatory Agents; Blood Transfusion; Follow-Up Studies; HIV Infections; Humans; Male;	1999
HIV-associated lymphoma: report of three cases. East African medical journal, 1999, Volume: 76, Issue:3 Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; CD4-CD8 Ratio; Cyclophosphamide; Doxorubicin;	1999
Aortic reconstruction in the HIV infected patient. Journal of medicine, 1999, Volume: 30, Issue:1-2 Topics: Aorta, Abdominal; Arterial Occlusive Diseases; Blood Vessel Prosthesis Implantation; Femoral Artery;	1999
Steroid-responsive nephrotic syndrome with minimal-change disease and IgA deposits in a HIV-infected patient. Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association, 2000, Volume: 15, Issue:3 Topics: Anti-HIV Agents; Antihypertensive Agents; Calcium Channel Blockers; Glomerular Mesangium; Glucocorti	2000
Favourable outcome of haemolytic uraemic syndrome in an HIV-infected patient treated only with prednisone. The Journal of infection, 2000, Volume: 41, Issue:1 Topics: Acute Kidney Injury; Adult; Anti-Inflammatory Agents; Antihypertensive Agents; Bronchoscopy; Ghana;	2000
Neutrophil-rich anaplastic large cell lymphoma of T-cell lineage. A report of two cases arising in HIV-positive patients. American journal of clinical pathology, 2000, Volume: 114, Issue:3 Topics: Adult; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Doxo	2000
[Bilateral hip necrosis, corticoids, and human immunodeficiency virus protease inhibitors]. Enfermedades infecciosas y microbiologia clinica, 2001, Volume: 19, Issue:1 Topics: Aged; Antiretroviral Therapy, Highly Active; Dexamethasone; Didanosine; Femur Head Necrosis; HIV Inf	2001
HIV-associated non-Hodgkin lymphoma: incidence, presentation, and prognosis. JAMA, 2001, Apr-11, Volume: 285, Issue:14 Topics: Antineoplastic Combined Chemotherapy Protocols; Antiretroviral Therapy, Highly Active; Biopsy, Needl	2001
Acute abdomen in an HIV-positive man. AIDS clinical care, 1997, Volume: 9, Issue:5 Topics: Abdominal Pain; Anti-HIV Agents; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; D	1997
Hybrid protocols plus natural treatments for inflammatory conditions. Positive health news, 1998,Fall, Issue:No 17 Topics: Anti-Inflammatory Agents; Complementary Therapies; Dietary Supplements; Drug Resistance, Microbial;	1998
Ciliochoroidal effusion and pulmonary hypertension in a patient with human immunodeficiency virus infection. Retina (Philadelphia, Pa.), 2001, Volume: 21, Issue:6 Topics: Choroid Diseases; Diuretics; Epoprostenol; Exudates and Transudates; Female; Fluorescein Angiography	2001
Efavirenz-induced leukocytoclastic vasculitis. Archives of internal medicine, 2002, Feb-11, Volume: 162, Issue:3 Topics: Adult; Alkynes; Anti-HIV Agents; Benzoxazines; Biopsy, Needle; Cyclopropanes; Drug Therapy, Combinat	2002
AIDS-related systemic non-Hodgkin's lymphoma at a large community program. AIDS research and human retroviruses, 2002, Mar-01, Volume: 18, Issue:4 Topics: Adult; Anti-HIV Agents; Antineoplastic Combined Chemotherapy Protocols; Base Sequence; Bleomycin; CD	2002
Bilateral peripheral facial palsy secondary to lymphoma in a patient with HIV/AIDS: a case report and literature review. The Brazilian journal of infectious diseases : an official publication of the Brazilian Society of Infectious Diseases, 2002, Volume: 6, Issue:1 Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Doxorubicin; Facial Paralys	2002
[Hodgkin's disease and infection with human immunodeficiency virus]. Sangre, 1992, Volume: 37, Issue:1 Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Cyclophosphamide; Dacarbazine; Dox	1992
A pilot study of oral corticosteroid therapy for idiopathic esophageal ulcerations associated with human immunodeficiency virus infection. The American journal of medicine, 1992, Volume: 93, Issue:2 Topics: Acquired Immunodeficiency Syndrome; Administration, Oral; Adult; Esophagitis; Female; HIV Infections	1992
Prednisone management of HIV-associated recurrent oral aphthous ulcerations. Journal of acquired immune deficiency syndromes, 1992, Volume: 5, Issue:9 Topics: Adult; HIV Infections; Humans; Middle Aged; Prednisone; Recurrence; Stomatitis, Aphthous	1992
Bilateral optic neuropathies with remission in two HIV-positive men. Journal of clinical neuro-ophthalmology, 1992, Volume: 12, Issue:1 Topics: Adult; HIV Infections; HIV Seropositivity; Humans; Male; Optic Nerve Diseases; Prednisone; Prognosis	1992
Recurrent aphthous ulcers in association with HIV infection. Diagnosis and treatment. Oral surgery, oral medicine, and oral pathology, 1992, Volume: 73, Issue:3 Topics: Acquired Immunodeficiency Syndrome; Administration, Topical; Adult; Anti-Inflammatory Agents; Clobet	1992
Prednisone improves human immunodeficiency virus encephalopathy in children. The Pediatric infectious disease journal, 1992, Volume: 11, Issue:1 Topics: Brain Diseases; Child, Preschool; Female; HIV Infections; Humans; Infant; Prednisone	1992
Meningitis with Burkitt like B-cell lymphoma in HIV infection. Journal of neuro-oncology, 1992, Volume: 13, Issue:1 Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Burkitt Lymphoma; Cyclophosphamide; Doxorubic	1992
Hypereosinophilic syndrome with unusual cutaneous manifestations in two men with HIV infection. Journal of the American Academy of Dermatology, 1990, Volume: 23, Issue:2 Pt 1 Topics: Adrenal Cortex Hormones; Adult; Dermatitis, Exfoliative; Eosinophilia; HIV Infections; Humans; Male;	1990
Human immunodeficiency virus wasting syndrome may represent a treatable myopathy. Neurology, 1990, Volume: 40, Issue:3 Pt 1 Topics: Acquired Immunodeficiency Syndrome; Adult; HIV Infections; HIV Seropositivity; Humans; Middle Aged;	1990

prednisone and HIV Coinfection

Research Excerpts

Research

Studies (188)

Authors

Clinical Trials (10)

Trial Overview

Trial Outcomes

Complete Response Proportion as Measured by Tumor Response After Completion of Study Treatment

Event-free Survival (EFS) (Phase II)

Overall Survival (OS) (Phase II)

Percentage of Participants With Complete Response (CR) as Assessed by Response Evaluation Criteria in Solid Tumors (Phase II)

Recommended Phase II Dose of Vorinostat Determined According to Dose-limiting Toxicities Graded Using Common Terminology Criteria for Adverse Events Version 4.0 (CTCAE v4.0) (Phase I)

Change in CD8 Cell Counts (Phase I)

Change in Plasma Associated Human Immunodeficiency Virus (HIV)-1 Ribonucleic Acid (RNA) (Phase I)

Changes in Absolute CD4 Cell Counts (Phase I)

Changes in Epstein-Barr Virus (EBV) Viral Load

Changes in Human Herpes Virus (HHV)-8 Viral Load

Changes in Human Herpes Virus (HHV)-8 Viral Load

Changes in Human Immunodeficiency Virus (HIV) Viral Load

Percentage of Participant Experiencing Adverse Events (AEs) for Each Treatment Arm as Assessed by Common Terminology Criteria for Adverse Events Version 4.0 (CTCAE v4.0) (Phase II)

Pharmacokinetic Clearance (Phase I)

Tumor Response (Phase I)

Alpha-1 MP vs. Prolastin® of Area Under the Curve (AUC) From Day 0 to Day 7

Complete Response Rate (Complete Response and Complete Response Unconfirmed) Defined as Disappearance of All Evidence of Disease Based on Radiographic Findings on CT or MRI .

Reviews

Trials

Other Studies